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1. INTRODUCTION 
The microbiota of the human gastrointestinal (GI) tract plays a pivotal role in 
human health. Different biologic functions, such as digestion of essential 
nutrients, maturation of intestinal epithelial cells, and impact on baseline 
physiologic parameters, including systemic effects on blood lipids, inhibition of 
harmful bacteria, and stimulation of the immune system, have been attributed to 
the microbiota through careful scientific evaluations over many decades 
(McFarland, 2000b; Eckburg et al., 2005; Canny and McCormick, 2008; 
Sharma et al., 2011; Greenblum et al., 2012). 
However, the declined birth rates and longer life expectancy in developed 
countries have led to increased prevalence of chronic disorders like cardio-
vascular disease and different metabolic disorders (WHO, 2003). Moreover, 
several respiratory and foodborne infections, and chronic diseases like urinary 
tract and Helicobacter pylori infections are still emerging (Foxman, 2003; 
Azevedo et al., 2009; Vouloumanou et al., 2009; Newell et al., 2010). Although 
the prevalence of H. pylori infection has been declining in Estonia (Oona et al., 
2004), gastritis, peptic ulcer disease and its general consequences on health such 
as gastric malignancies still need attention. All this requires population based 
new preventive approaches, namely infection control and improved nutrition. 
Functional food is the food that contains some health-promoting components 
beyond traditional nutrients. Examples of functional food include foods com-
prising specific dietary fibre, foods with added biologically active substances 
such as antioxidants or phytochemicals and probiotics (Stanton et al., 2005; Siro 
et al., 2008). Probiotics are defined as live microorganisms which, when admi-
nistered in adequate numbers confer a health benefit on the host (FAO/WHO, 
2001). In clinical trials consumption of probiotic food comprising different 
lactic acid bacteria has shown several scientifically established and/or clinically 
proved health effects as prevention of particular infections and non-infectious 
disorders (McFarland, 2000a; Salminen, 2001; Minocha, 2009; Floch et al., 
2011). However, studies focusing on expression of functional properties of a 
probiotic on healthy persons are lacking. 
The Department of Microbiology of the University of Tartu has participated 
in national and several international projects, namely in the EU 5th, 6th and 7th 
Framework Programs, in cooperation with other European universities for 
assessment of the functional properties, safety and efficacy of some commercial 
and potential probiotics of lactic acid bacteria. 
The present thesis specifies on evaluation of the functional properties (anta-
gonistic and antioxidative activity) of seven commercial probiotics included in 
the EU 5th FP “Microfunction” with 5 European universities and enterprises. 
Three strains and a fructo-oligosaccharides preparation were selected according 
to the results of in vitro experiment for efficacy testing of a synbiotic product. 
The aim was to assess the impact of the synbiotic after consumption of capsules 
containing commercial probiotics with prebiotic raftilose P95 on health indices, 
4
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biochemical markers and faecal microbiota through research conducted by 
different university partners. In the present study the efficacy was assessed by 
measuring blood oxidative stress related indices in healthy volunteers. 
Next, screening of the putative probiotics which have been collected from 
various studies and deposited in the Human Microbiota Biobank (acronym: 
HUMB, registration number: 977) was performed. Colonizing potential in vitro 
was assessed. To determine the safety parameters of the selected Lactobacillus 
strains, in vitro tests and an animal model was applied. 
The survival and persistence of these strains in healthy volunteers were 
assessed in clinical trials. In a human intervention trial, the safe consumption of 
the high doses of the lactobacilli was assessed according to a self-reported ques-
tionnaire and clinical parameters in cooperation with scientists of the Karolinska 
Institute, Sweden in the course of EU 6th FP “Biodefence”. 
The author of the current PhD thesis has also participated in the charac-
tertization and safety testing of the probiotic strain Lactobacillus plantarum 
TENSIA (DSM 21380). This strain has been patented in Estonia (Estonian 
Patent No 05340) and the international patent application 
(PCT/EE2009/000005) has been filed. This probiotic is characterized by 
antimicrobial and antihypertensive effect and the author of the thesis has 
evaluated the functional properties of the strain and its safety in healthy 
volunteers. The collection and evaluation of the clinical data were performed at 
the Department of Microbiology and at the Department of Biochemistry of the 
University of Tartu and at the Bio-Competence Centre of Healthy Dairy 
Products LLC, Estonia.  
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2. REVIEW OF THE LITERATURE 
2.1. Beneficial intestinal bacteria 
The intestine harbors an ecosystem composed of the intestinal mucosa, the 
digestive secretions and the commensal microbiota. The normal gut ecosystem 
can efficiently block intrusion of many pathogenic bacteria. This has been 
termed ‘microbial interference’ or ‘colonization resistance’ (van der Waaij et 
al., 1971). 
Lactobacillus sp. and Bifidobacterium sp. are microorganisms that form part 
of the human microbiota, having an important role in the first line of defence 
against opportunistic and invasive pathogens (Stecher and Hardt, 2008). 
Moreover, the diseases and disorders such as inflammatory bowel disease, 
irritable bowel syndrome and obesity are associated with human gut microbiota 
where aberrations could be improved by consuming probiotic lactobacilli and 
bifidobacteria (Fujimura et al., 2010). The underlying mechanisms depend on 
particular functional properties of different strains of the mentioned genera and 
species. 
 
 
2.1.1. Lactobacillus spp. 
Lactic acid bacteria (LAB) are a heterogeneous group of bacteria, many of them 
having received a generally recognized as safe (GRAS) or qualified pre-
sumption of safety (QPS) –status. These bacteria are widely found in nature, 
including the GI and urogenital tracts of humans and animals, and are present in 
many fermented foods like salted gherkins, marinated olives, capers and salami, 
and different milk based products such as cheese and yoghurt (Tannock, 2004). 
LAB are gram-positive, acid-tolerant and non-spore forming cocci and rods. 
They are a heterogeneous group of bacteria comprising about 20 genera within 
the phylum Firmicutes. From the practical point of view the genera Aerococcus, 
Carnobacterium, Enterococcus, Lactobacillus, Lactococcus, Leuconostoc, 
Oenococcus, Pediococcus, Streptococcus, Tetragenococcus, Vagococcus and 
Weissella have been considered as the principal LAB (Kandler and Weiss, 
1986; Klein et al., 1998; Holzapfel et al., 2001; Axelsson, 2004). 
The genus Lactobacillus is the largest LAB group comprising over 145 
recognized species and 30 subspecies (Bernardeau et al., 2008; Claesson et al., 
2008). These numbers are constantly being re-evaluated on the basis of modern 
methods of molecular biology and whole genome-based techniques (Makarova 
et al., 2006; Felis and Dellaglio, 2007). 
The classical way to distinguish between species of lactobacilli is based on 
the phenotypic properties of lactobacilli. According to carbohydrate fermen-
tation patterns and growth at certain temperatures, the genus Lactobacillus is 
divided into homofermentative lactobacilli (OHOL), facultatively hetero-
fermentative lactobacilli (FHEL), and obligately heterofermentative lactobacilli 
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(OHEL) subgroups (Kandler and Weiss, 1986; Klein et al., 1998). The 
carbohydrate metabolism of lactobacilli usually allows taxonomic differen-
tiation between species with the use of commercial kits (like API 50 CHL by 
bioMérieux). 
A previous study has shown discrepancies in the identification of lactobacilli 
by API and Internal Transcribed Spacer PCR (ITS-PCR). The species of one-
third of Lactobacillus strains were renamed according to the results of 
molecular typing techniques (ITS-PCR) (Annuk et al., 2003). 
Moreover, if one uses 16S phylogeny, then the Lactobacillus species can be 
divided into three groups: the L. casei-Pediococcus group, the Leuconostoc 
group and the Lactobacillus acidophilus/delbrueckii group (Collins et al., 1991; 
Stiles and Holzapfel, 1997). Since then, based again on 16S rDNA sequences, it 
was proposed to divide the Lactobacillus species into five groups, namely L. 
acidophilus, L. salivarius, L. reuteri, L. buchneri and L. plantarum (Schleifer 
and Ludwig, 1995). 
However, these classifications have generally been considered as unsatis-
factory and the use of 16S rRNA genes as phylogenetic markers has been 
criticized (Claesson et al., 2008). As complete genome sequences have become 
available, the high diversity of Lactobacillus has also been suggested to require 
the creation of new, subgeneric divisions (Canchaya et al., 2006; Claesson et 
al., 2008). 
 
 
2.1.2. Bifidobacterium spp. 
Bifidobacteria can be found all along the GI tract and the main species present 
in humans are Bifidobacterium adolescentis, B. bifidum, B. infantis, B. breve 
and B. longum (Crociani et al., 1996; Marteau et al., 2001; Nielsen et al., 2003). 
Bifidobacteria are gram-positive, heterofermentative, non-motile, non-sporu-
lating bacteria. They vary in size and exhibit rods of various shapes, often in ‘V’ 
or ‘Y’ patterns (Latin bifidus: cleft, divided). Bifidobacteria are often included 
in the group of LAB due to their metabolic capacities and the sharing of 
ecological niches (Klein et al., 1998).  
The genus Bifidobacterium is relatively small with ca 32 identified species 
to date, mainly of human or animal origin and has a low level of phylogenetic 
and genomic diversity (Ventura et al., 2006). Bifidobacteria belong to the 
phylum Actinobacteria (Ventura et al., 2007). Bifidobacteria are reported to 
possess a route for the metabolism of hexose, the fructose-6-P phosphoketolase 
(F6PPK) pathway (the so-called bifid shunt) (de Vries et al., 1967). Lactic and 
acetic acids are produced as metabolic end products from hexose fermentation. 
F6PPK activity is one of the main phenotypic features used to identify bifido-
bacteria at the genus level. The second pathway involves the splitting of 
pyruvate by a phosphoroclastic enzyme to form formic acid and acetyl phos-
phate (Scardovi, 1986). 
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2.2. Gastrointestinal pathogens 
GI pathogens infect the host in different ecological niches with particular 
environmental conditions of the GI tract. Helicobacter pylori resides under 
microaerobic conditions in the stomach. Salmonella sp. causes inflammation in 
the ileum and colon, while Shigella sp. clearly prefers the more anaerobic 
conditions on the colonic mucosa (Dupont, 2005; Pegues et al., 2005). In 
addition, the colon has been considered the main reservoir of E. coli strains 
causing urinary tract infections (Franz and Horl, 1999).  
 
 
2.2.1. Gastric pathogen Helicobacter pylori 
Helicobacter pylori is a gram-negative, spiral-shaped, non-spore-forming 
microaerophilic bacterium that resides in harsh conditions of the gastric cavity 
and mucosa. H. pylori is associated with severe gastric pathologies, including 
chronic active gastritis, peptic ulcer, gastric adenocarcinoma, and type B low-
grade mucosa-associated lymphoid tissue lymphoma (Dunn et al., 1997; 
Kandulski et al., 2008). H. pylori is classified as grade 1 carcinogen by the 
World Health Organization in 1994 (IARC, 1994). It has been suggested that 
H. pylori infection is also associated with several extragastric systemic diseases 
(cardiovascular and neurodegenerative diseases) and ocular diseases, and 
dermatological disorders (Izzotti et al., 2009). DNA damage and failure of 
antioxidant defences is a common denominator of many among these patho-
logical conditions. The clinical outcome of H. pylori infection is dependent on 
many variables, including H. pylori genotype, host health status, host genotype, 
and host exposure to environmental factors (Kandulski et al., 2008). Infection 
with H. pylori invariably leads to a chronic inflammatory response (chronic 
active gastritis with lymphocytes infiltration), yet most infected patients remain 
asymptomatic (Dunn et al., 1997). 
Approximately 50% of the world’s population is infected with H. pylori (Go, 
2002). Various risk factors for infection include lower socioeconomic status, 
younger age, and geographic location (Bruce and Maaroos, 2008). The 
prevalence of H. pylori is decreasing in developed countries, while it is still 
high in developing countries (Hunt et al., 2011). Infection is usually acquired in 
childhood and in the absence of antibiotic therapy persists for the life of the host 
(Everhart, 2000). 
There are two types of diagnostic tests used to detect H. pylori infection: 
noninvasive and invasive. Noninvasive tests include the urea breath test (UBT), 
stool antigen tests and serology blood tests. Noninvasive tests detect the 
presence or absence of infection. Invasive tests include performance of upper 
gastrointestinal endoscopy with gastric biopsy. Invasive tests can determine 
both presence/absence of infection and the extent and severity of mucosal injury 
(Monteiro et al., 2009). 
5 
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Although several diagnostic tests are available for the detection of H. pylori 
infection, all of them have both advantages and disadvantages, and none can be 
considered as a single gold standard. A combination of endoscopic biopsy-
based methods (such as rapid urease testing, histologic examination, culture, 
and PCR) usually provides the most reliable diagnosis (Maaroos et al., 2004).  
However, these methods are invasive, expensive, and not always applicable. 
Therefore, there is an increasing interest in non-invasive tests for H. pylori 
detection. The UBT is considered to be the most accurate non-invasive method 
to detect H. pylori infection. Stool antigen tests have been extensively evaluated 
in pre- and post-treatment settings both in adults and children (Dzierzanowska-
Fangrat et al., 2006). Monoclonal stool antigen test (e.g. HpSA) is an accurate 
noninvasive method both for the initial diagnosis of H. pylori infection and for 
the confirmation of its eradication after treatment. The monoclonal technique 
has higher sensitivity than the polyclonal technique, especially in the post-
treatment setting (Gisbert et al., 2006).  
 
 
2.2.2. Other enteric pathogens 
Salmonella sp., Shigella sp. and Escherichia coli are gram-negative, facul-
tatively anaerobic, rod-shaped bacteria. Different Salmonella serovars are 
responsible for human diseases ranging from gastroenteritis to systemic infec-
tions (Falkow, 2006). Shigella species, particularly S. sonnei and S. flexneri, 
cause shigellosis in developed countries and globally (Deer and Lampel, 2010). 
Due to different virulence factors of E. coli, various infections may appear: 
gastroenteritis, urinary tract infections, meningitis, and wound infections (Kaper 
et al., 2004). 
Clostridium difficile is an anaerobic, gram-positive, spore-forming bacillus. 
The symptoms of C. difficile infection can range from mild diarrhea to serious 
manifestations such as pseudomembranous colitis, toxic megacolon or per-
foration of the colon. C. difficile causes commonly nosocomial antibiotic-
associated diarrhea (AAD) but it may also be related to community-acquired 
infection with no previous exposure to antibiotics in children, pregnant women 
and patients with inflammatory bowel disease (IBD). In recent years, a 
hypervirulent strain (e.g. NAP1/BI/027), with fluoroquinolone resistance has 
emerged. It may lead to severe GI infection and even to mortality (Anan-
thakrishnan, 2011). 
 
 
2.3. Oxidative stress 
Oxygen has a central role in the evolution of aerobic life on Earth. Aerobic 
organisms use molecular oxygen to generate chemical energy in the form of 
adenine triphosphate (ATP). However, oxidation may result in overproduction 
of toxic molecules, e.g. reactive oxygen species (Buonocore et al., 2010). 
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Reactive oxygen species (ROS) and reactive nitrogen species (RNS, e.g. 
nitric oxide, NO) are well recognised for playing a dual role as both beneficial 
and deleterious species. ROS and RNS are normally generated by tightly 
regulated enzymes, such as NO synthase (NOS) and NAD(P)H oxidase iso-
forms, respectively. The beneficial effects of ROS/RNS occur at low/moderate 
concentrations and involve a physiological role in cellular responses to noxia, as 
for example, in defence against infectious agents, in the function of a number of 
cellular signalling pathways, and in the induction of mitogenic response (Valko 
et al., 2007). In contrast, overproduction of ROS (arising either from the 
mitochondrial electron transport chain or excessive stimulation of NAD(P)H) 
results in oxidative stress, a deleterious process that can be an important 
mediator of damage to cell structures, including membranes and molecules as 
lipids, proteins, DNA and carbohydrates. 
Oxidative stress is defined as an imbalance between pro-oxidants (ROS, 
RNS) and antioxidants in favor of pro-oxidants (Sies and Cadenas, 1985; Halli-
well, 2009). This imbalance may be due to an excess of pro-oxidant agents, a 
deficiency of antioxidant agents or both factors simultaneously.  
An excessive and/or sustained increase in ROS production has been 
implicated in the pathogenesis of infections, cancer, diabetes mellitus, athero-
sclerosis, neurodegenerative diseases, rheumatoid arthritis, ischemia/reperfusion 
injury, obstructive sleep apnea, and other diseases (Dröge, 2002). 
The human body has evolved an integrated antioxidant defence system 
consisting of nonenzymatic antioxidants, such as reduced glutathione (GSH), 
vitamin E, C, Q10, blood albumin, uric acid, bilirubin and enzymatic anti-
oxidants (e.g. superoxide dismutase, glutathione peroxidase, catalase and heme 
oxygenase) (Gutteridge and Halliwell, 2000). An increase in antioxidants might 
be interpreted as the situation with “lower oxidative stress” (Bashan et al., 
2009). 
Oxidative stress is also defined as ‘a disruption of redox signalling and 
control’ that emphasizes an impact of GSH and its redox ratio (GSH/GSSG) as 
good tools for the quantification of oxidative stress (Jones, 2006). 
Determination of oxidative stress is mainly based on determination of oxi-
datively modified compounds (e.g. oxidized low-density lipoprotein (oxLDL), 
baseline diene conjugates of low-density lipoprotein (BDC-LDL), and anti-
oxidative capacity of blood sera (e.g. total antioxidative activity (TAA) and 
total antioxidative status (TAS) (Ahotupa et al., 1998; Ahotupa and Asankari, 
1999; Kullisaar et al., 2003; Songisepp et al., 2005; Kullisaar et al., 2011). 
 
 
2.4. Functional food 
Diet and nutrition are important factors in the promotion and maintenance of 
good health throughout the entire life-course. However, rapid changes in diets 
and lifestyles have a significant impact on the health and nutritional status of 
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populations. While the standards of living have improved, food availability has 
expanded and become more diversified. There have also been significant nega-
tive consequences in terms of inappropriate dietary patterns, decreased physical 
activities and increased tobacco use, and a corresponding increase in non-
communicable diet-related chronic diseases (e.g. obesity, diabetes mellitus type 
2, cardiovascular disease, hypertension and stroke, and some types of cancer) 
(WHO, 2003). 
Functional food (FF) is a natural food, to which a component has been 
added/removed or a food in which the bioavailability of the components has 
been modified by technological or biotechnological means (Roberfroid, 2000a). 
FF includes conventional foods, modified foods (fortified, enriched, or 
enhanced), medical foods, and foods for special dietary use (Siro et al., 2008; 
Hasler and Brown, 2009). FF can play an important role in the risk reduction of 
non-communicable diseases and can prolong remission in IBD (including 
Crohn’s disease and ulcerative colitis) and alleviate allergic conditions by 
providing benefits beyond usual nutrition as well as in optimising health and 
general well-being (ILSI, 2009; Fujimura et al., 2010). 
The European Commission Concerted Action on Functional Food Science in 
Europe (FUFOSE) proposed a working definition of functional food: a food that 
beneficially affects one or more target functions in the body beyond adequate 
nutritional effects in a way that is relevant to either an improved state of health 
and well-being and/or reduction of risk of disease. It is consumed as part of a 
normal food pattern: it is not a pill, a capsule or any form of dietary supplement 
(EC, 2010). 
Essential attributes or characteristics of functional foods are the following: 
form and sensory characteristics (colour, texture, consistency and flavour, 
including appearance in conventional food). Second, contain nutrients and/or 
other substances that confer a physiological benefit over and above their basic 
nutritional properties. Third, possess functional benefits that can be scientifi-
cally proven and accepted by the relevant regulatory authority. Fourth, possess 
functional benefits that can be derived by consuming normal amounts of the 
foods. Fifth, contain an adequate amount of ‘functional’ nutrients and/or other 
substances that produce the claimed effect/in relation to the claimed effect and 
last, have been proven to be safe during long term usage by the intended target 
population, based on existing science. FF should not be intended for medical or 
therapeutic use (ILSI, 2009). 
The most promising targets for FF are the GI functions and particularly 
control of nutrient bioavailability (Roberfroid, 2000b). However, FF may affect 
different other systems in the body: balanced colonic microbiota, control of 
transit time and mucosal motility, bowel habits; modulation of epithelial cell 
proliferation, balance of redox and antioxidant systems, metabolism of macro-
nutrients, especially amino acids, carbohydrates and fatty acids. 
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2.4.1. Probiotics 
Probiotics (the name is derived from the Greek ‘for life’) have been used for 
about 100 years. Today they are applied for treatment of a variety of infections 
of the intestinal tract or the vagina, where the use of antibiotics coincides with 
adverse shifts in microbial ecology. Moreover, these agents are sometimes 
being reconsidered as alternatives to antibiotics because of the rise in antibiotic-
resistant strains of bacteria (D’Souza et al., 2002). The term ‘probiotic’ was 
initially used in the 1950s and the definitions of probiotic have been refined as 
more experience has been gained, the most widely used being ‘live micro-
organisms which when administered in adequate amounts confer a health 
benefit on the host’ (FAO/WHO, 2001). Different definitions of the first genera-
tion of probiotics are listed in Table 1. 
Table 1. Descriptions and definitions of probiotics suggested over time. 
Published definition  Reference 
Probiotics are opposite of antibiotics. Vergin, 1954 
Substances produced by microorganisms which promote the growth 
of other microorganisms. 
Lilly and 
Stillwell, 1965 
Organisms and substances that contribute to intestinal microbial 
balance. 
Parker, 1974 
A live microbial feed supplement which beneficially affects the 
host animal by improving its intestinal microbial balance. 
Fuller, 1989 
A viable mono- or mixed-culture of microorganisms which applied 
to animal or man, beneficially affects the host by improving the 
properties of the indigenous microflora. 
Havenaar and 
Huis in’t 
Veld, 1992 
A live microbial culture or a cultured dairy product which 
beneficially influences the health and nutrition of the host. 
Salminen, 
1996 
Living microorganisms, which upon ingestion in certain numbers, 
exert health benefits beyond inherent basic nutrition. 
Schaafsma, 
1996 
A microbial dietary adjuvant that beneficially affects the host 
physiology by modulating mucosal and systemic immunity, as well 
as by improving nutritional and microbial balance in the intestinal 
tract. 
Naidu et al., 
1999 
A preparation of or a product containing viable, defined 
microorganisms in sufficient numbers, which alter the microflora 
(by implantation or colonization) in a compartment of the host and 
by that exert beneficial health effects in this host.  
Schrezenmeir 
and de Vrese, 
2001 
Live microorganisms which, when administered in adequate 
amounts confer a health benefit on the host. 
FAO/WHO, 
2001 
A probiotic product is a strain-specific preparation targeting diffe-
rent human metabolic functions to improve health by either suppor-
ting host physiologic activity or by reducing the risk of disease. 
Mikelsaar et 
al., 2011 
6
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Today, there is increasing interest in developing the second generation of 
probiotics, so called novel genetically engineered probiotics, or “designer 
probiotics” to combat pathogenic microorganisms (Ahmed, 2003; Celec et al., 
2005; Sleator and Hill, 2009) or to help alleviate inflammatory processes in the 
colon (IL-10 or trefoil factor secreting strains) (Steidler and Rottiers, 2006). 
Probiotics provide beneficial effects on the host’s health by affecting the 
intestinal microbiota. Their beneficial effects on human health, such as 
alleviation of lactose intolerance, immunomodulation, decrease in faecal car-
cinogenic enzymes and mutagenicity, hypocholesterolemic effect, and short-
ening of the duration of acute infectious diarrhea have been demonstrated in 
many studies (Salminen, 2001; Shah, 2007; Delcenserie et al., 2008; Vasiljevic 
and Shah, 2008; Allen et al., 2010). 
LAB including lactobacilli and bifidobacteria are commonly used as 
probiotics, either as monostrain or multistrain (or multispecies) microorganisms 
(Timmerman et al., 2004). Also other microbial species besides LAB like 
Enterococcus faecalis, Escherichia coli, Propionibacterium sp. and yeasts 
(Saccharomyces boulardii) have been accepted and used as probiotics (Prado et 
al., 2008). 
Probiotics can be administered as a component of functional food (yoghurt, 
cheese, milk) or as food additives (e.g. capsules, tablets). For the general popu-
lation, outpatient and hospital patient probiotics have been applied. There is a 
need for more comparative clinical studies where the dosage, and number of 
different strains in combination could be evaluated for their survival, coloni-
zation potential and safety for the host. 
 
 
2.4.2. Prebiotics 
A prebiotics formula can be included in a wide range of foods, such as bakery, 
and dairy products and beverages. Prebiotics were originally defined as ‘a non-
digestible food ingredient that beneficially affects the host by selectively 
stimulating the growth and/or activity of one or a limited number of bacteria in 
the colon that can improve the host health (Gibson and Roberfroid, 1995). 
Generally, prebiotics are specific oligosaccharides or more complex saccharides 
that are selectively metabolized for different compounds by some commensal 
groups of microorganisms, including species considered to be beneficial for the 
host. 
The concept of prebiotics has been formalized by the establishment of three 
scientific criteria for a food ingredient to be considered as prebiotic (Gibson et 
al., 2004): (i) resistance to gastric acidity and hydrolysis by mammalian 
enzymes and GI absorption; (ii) substrate of fermentation by intestinal micro-
organisms belonging to the human microbiota; and (iii) selective stimulation of 
the growth and/or activity of intestinal bacteria associated with health and 
wellbeing. 
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Prebiotics include nondigestible fructo-oligosaccharides (FOS) (e.g. inulin), 
oligofructose and transgalacto-oligosaccharides (GOS) (Candela et al., 2010). 
With an impact on the composition and metabolism of gut microbiota, pre-
biotics and their derived metabolites can exert different functional properties, 
such as prevention of pathogen adhesion and colonization; modulation of bowel 
habits; regulation of lipid and glucose metabolism (Laparra and Sanz, 2010).  
It has been recently reported that oligofructose supplementation lowers 
hunger, promotes weight loss and improves glucoregulation in obese and 
healthy adults (Parnell and Reimer, 2009).  
The mechanism by which the nutritional modulation of the gut microbiota 
by prebiotics impacts on appetite sensation is poorly understood, however, a 
fascinating hypothesis has been advanced (Cani et al., 2009). Particularly, the 
increase in short-chain fatty acid (SCFA) production due to oligofructose 
fermentation by intestinal microorganisms may stimulate the biosynthesis of the 
satiety inducing hormones, such as glucagon-like peptide 1 (GLP-1), peptide 
YY (PYY) and ghrelin.  
Earlier there have also been reported the positive effects of prebiotic con-
sumption such as reduction of osteoporosis by improved mineral absorption; 
reduction of allergy risk through immune system modulation and reduction of 
colon cancer risk (Roberfroid, 2000b). Many of the above mentioned health 
claims still require further research. 
 
 
2.4.3. Synbiotics 
Prebiotics are the most frequent target substance for bifidobacteria and lacto-
bacilli. The term synbiotic is used when referring to a product that contains a 
prebiotic and a probiotic in combination (Roberfroid, 1998). Synbiotics are 
mixtures that improve the survival and implantation of live microbial dietary 
supplements in the GI tract, either by stimulating growth or by metabolically 
activating health promoting bacteria (Kaur et al., 2002). Saulnier and co-
workers, studying various compositions of probiotic bacteria and prebiotics, 
have shown that certain synbiotics may have superior effects, compared with 
probiotics alone, in modulating the faecal microbiota (Saulnier et al., 2008). 
There are reports indicating the efficacy of a synbiotic supplementation in 
prevention of common winter diseases in children and improvement in the 
clinical appearance of active ulcerative colitis (Furrie et al., 2005; Cazzola et 
al., 2010). However, there is a lack of studies where the impact of different 
functional properties of probiotics and the metabolic pool of prebiotics on 
metabolic indices and oxidative stress related markers are properly investigated 
in clinical efficacy studies. 
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2.5. Regulation and guidelines  
for the evaluation of probiotics 
2.5.1. EU regulation on nutrition and health claims 
Regulation (EC) No 1924/2006 of the European Parliament and Council of 20 
December 2006 on nutrition and health claims made on foods covers all foods, 
including food supplements and foodstuffs for particular nutritional uses, and 
concerns nutrition and health claims in advertisements, labelling and presen-
tation of foods to consumers. Regulation 1924/2006 identifies two categories of 
claims on foods: nutrition claims and health claims. In the context of EU 
Regulation 1924/2006, health claims are claims that state, suggest or imply a 
relationship between a food or food category and health. Examples hereof are 
function claims, reduction of risk of disease claims, or claims referring to the 
growth and development of children. Nutrition claims are claims that state, 
suggest or imply that a food has particular beneficial nutritional properties due 
to the energy it provides or the nutrients it contains (EC, 2006; Verhagen et al., 
2010). 
Health claims on (functional) foods must be scientifically substantiated. The 
European Food Safety Authority (EFSA) provides scientific advice to the 
European Commission for health claims (Verhagen et al., 2010). The settled 
regulations also demand more scientific evidence based research regarding pro-
biotics and prebiotics. 
 
 
2.5.2. Guidelines for evaluation of probiotics 
A joint working group of the FAO and the WHO developed guidelines to assess 
the efficiency and safety of probiotics in food. The FAO and WHO focused on 
guidelines and recommendations for the criteria and methodologies required to 
identify and define probiotics and to establish the minimum requirements 
needed to accurately substantiate health claims (Figure 1) (FAO/WHO, 2002). 
 
2.5.2.1. Screening of putative probiotic strains 
To screen intestinal lactobacilli strains for their advantageous properties for 
development of novel gastrointestinal probiotics involves a step-wise process in 
order to obtain a functional and safe product.  
Though the genus Lactobacillus has a Generally Recognized As Safe 
(GRAS) and qualified presumption of safety (QPS) status, and a long history of 
safe use for food fermentation, several criteria must be taken into consideration 
to select and evaluate a putative probiotic Lactobacillus strain (FAO/WHO, 
2002; Reid et al., 2003; EFSA, 2011b). The properties of a putative probiotic 
must be thoroughly described in vitro as well as in vivo animal studies and in 
clinical trials. 
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Selection criteria for probiotics are an area of much debate and should be 
taken into account when defining appropriate strains. The following criteria 
have been suggested for use in probiotic strain selection (Figure 1) (Saarela et 
al., 2000; FAO/WHO, 2002; Reid et al., 2003; Vankerckhoven et al., 2008): 
1. General aspects (origin, identity) 
2. Safety 
3. Functional features 
4. Technological aspects 
 
The minimium requirements needed for probiotic status include the assessment 
of strain identity, in vitro tests to screen potential functional properties and 
colonizing potential of probiotics, assessment of safety above all, and in vivo 
studies for substantation of effects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. FAO and WHO (2002) guidelines for evaluation of probiotics for food use. 
Strain identification by phenotypic and genotypic methods 
 Genus, species, strain 
 Deposit strain in international culture collection 
Functional characterization 
 In vitro tests 
 Animal studies 
Safety assessment 
 In vitro and/or animal  
 Phase 1 human study 
Double blind, randomised, placebo-controlled  
(DBPCT) phase 2 human trial or other 
appropriate design with sample size and 
primary outcome appropriate to determine  
if strain/product is efficacious 
Preferably second 
independent DBPCT 
study to confirm results 
Probiotic food 
Phase 3, effectiveness trial is 
appropriate to compare 
probiotics with standard 
treatment of a specific condition 
Labelling 
 Contents – genus, species, strain designation 
 Minimum numbers of viable bacteria at the end of 
shelf-life 
 Proper storage conditions 
 Corporate contact details for consumer information 
7 
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2.5.2.2. Origin, identification and typing of strains 
A microbial strain retains its functionality in an environment similar to that 
from which it was originally isolated. Therefore, a probiotic strain aimed for 
human use should be preferably isolated from the healthy human GI tract 
(Saarela et al., 2000). 
Correct assessment of taxonomic identity should be scheduled in the 
screening process for new probiotic candidate strains (Saarela et al., 2000; 
FAO/WHO, 2002; Vankerckhoven et al., 2008). Correct identification of 
probiotic strains to the species level is essential for safety assessment as it 
allows a linkage to potentially relevant, species-related scientific and techno-
logical information, including data on growth conditions, metabolic charac-
teristics and genomic information. In addition, strains must be identified to the 
strain level (FAO/WHO, 2002).  
The ability to identify a specific probiotic strain among other probiotics or 
members of the native microbiota is essential for strain selection and characteri-
zation, assessments of strain stability throughout the manufacturing process, for 
proper description of the material used in human intervention studies, for 
efficient tracking of the probiotic through the host, and for post-market surveil-
lance including matching of strains isolated from any suspected infections. 
Traditional methods used for detection of probiotics in the human GI tract 
include identification using colony morphology, fermentation patterns and com-
binations of these methods.  
Unfortunately, the use of phenotypic tests or commercial identification 
systems such as API (Huys et al., 2006; Vankerckhoven et al., 2008), are inade-
quate for species level resolution. These systems (e.g. API 50 CHL) may be 
useful to obtain a first tentative classification at the genus level and fermen-
tation type level, but the identification result should in any case be confirmed by 
other (molecular) methods (Vankerckhoven et al., 2008).  
Polyphasic identification uses a combination of genotypic and phenotypic 
approaches offering accurate identification and classification of closely related 
probiotic species (Vandamme et al., 1996; Gancheva et al., 1999). 
Typing methods (such as pulsed-field gel electrophoresis (PFGE) and ran-
domly amplified polymorphic DNA analysis (RAPD), amplified fragment 
length polymorphism (AFLP-PCR), repetitive DNA element (rep)-PCR and 
ribotyping) are primarily useful for differentiation of individual strains. 
At present, the inappropriate use of identification methods is considered to 
be the major cause of mislabeling of probiotic products reported worldwide 
(Temmerman et al., 2003; Masco et al., 2005). 
Reliable species identities of lactic acid bacteria are obtained by the use of 
pattern- and/or sequence-based molecular methods that provide sufficient 
experimental reproducibility and the proper taxonomic resolution. These 
methods make use of updated and easily available and validated identification 
databases (Vankerckhoven et al., 2008).  
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Besides molecular DNA-based typing, extraction of whole-cell proteins, 
followed by sodium dodecyl sulphate-polyacrylamide gel-electrophoresis (SDS-
PAGE) separation, has been found to be a reliable and rapid way to characterize 
a large number of strains (Reuter et al., 2002). 
 
2.5.2.3. Safety of probiotics 
Lactobacilli belong to the human normal microbiota of the GI and urogenital 
tracts. Moreover, lactobacilli have been used for many centuries in food fermen-
tation processes and have a long history. Lactobacilli are generally regarded as 
safe (Borriello et al., 2003). Therefore, the US Food and Drug Administration 
(FDA) has classified lactobacilli as GRAS (generally recognized as safe) 
organisms (Donohue, 2004). In Europe, the European Food Safety Authority 
(EFSA) has taken responsibility to launch the European initiative toward a 
“qualified presumption of safety” (QPS) concept which, similar to the GRAS 
system in the United States, is aimed to allow strains with an established history 
and safety status to enter the market without extensive testing requirements 
(EFSA, 2011b). 
It is believed that the risk of infection with a probiotic Lactobacillus strain is 
similar to the risk of becoming infected with a Lactobacillus strain from the 
commensal microbiota (Ishibashi and Yamazaki, 2001). Endocarditis, bac-
teraemia and localised infections including abscesses caused by lactobacilli 
have been reported but mainly in individuals with severe underlying disease 
(Cannon et al., 2005; Sanders et al., 2010). On the other hand, specific strains 
of Lactobacillus probiotics have been administered to immunocompromised 
patients with HIV and no concerns have been reported (Salminen et al., 2004). 
Other theoretical impact regarding the safety of putative probiotics include toxic 
or metabolic effects in the GI tract, transfer of antibiotic resistance to the GI 
microbiota (Snydman, 2008), and adverse effects mediated by immuno-
modulation (FAO/WHO, 2002; Sanders et al., 2010). 
In order to establish safety guidelines for probiotic organisms, recognizing 
that many are Generally Recognized as Safe, the FAO and WHO recommended 
that probiotic strains be characterized at a minimum with a series of tests: 
1) determination of antibiotic resistance pattern, 2) assessment of certain 
metabolic activities (d-lactate production, bile salt deconjugation), 3) assess-
ment of side effects in humans, 4) epidemiological surveillance of adverse 
incidents in consumers, 5) testing for toxin production, 6) testing for haemolytic 
activity, and 7) infectivity in immunocompromised animal models (FAO/WHO, 
2002). Saarela et al (2000) suggested additional evaluation of the non-patho-
genicity (no degradation of host mucins, no platelet aggregation properties) of 
putative probiotic strains.  
The safety of probiotics should be confirmed in studies of humans. Although 
many research tools based on animal models or in vitro techniques are avail-
able, data from studies of humans are preferred whenever possible. Different 
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self-reported questionnaires for monitoring symptoms and adverse effects have 
been applied (Borriello et al., 2003; Vankerckhoven et al., 2008; Vlieger et al., 
2009). The tolerance and safe administration of probiotics could be evaluated by 
noninvasive measurements, such as measurements of body weight or blood 
pressure, parameters of hematologic analysis and of serum/plasma chemical 
analysis (liver and renal function indices). 
Unfortunately, there is no generally accepted approach for safety assessment 
of probiotics, relying on differences in vitro, in animal experiments and in 
human intervention trials. 
 
2.5.2.3.1. Antibiotic resistance of putative probiotics 
There is concern about the antibiotic resistance of lactic acid bacteria being 
transferred to possibly pathogenic bacterial species, complicating the treatment 
of infection and leading to the spread of antibiotic-resistant bacteria (Mathur 
and Singh, 2005). Therefore, all probiotic products intended for use as feed or 
food additives must be examined to establish the susceptibility of the compo-
nent strain(s) to a relevant range of antibiotics, using internationally recognised 
and standardised methods (Vankerckhoven et al., 2008). There is a list of 
antibiotics, namely ampicillin, gentamicin, streptomycin, kanamycin, erythro-
mycin, clindamycin, tetracycline, chloramphenicol, ciprofloxacin and quin-
upristin with dalfopristin, that the European Food Safety Authority (EFSA) has 
suggestsed for detecting the antibiotic susceptibility pattern of lactobacilli 
(EFSA, 2008). These antibiotics belong to a group of broad-spectrum anti-
biotics that are intended for treatment of gram-negative pathogens. 
The presence of transmissible antibiotic resistance markers in the evaluation 
of strains is thus an important safety criterion. Today, 35 Lactobacillus species 
(including L. acidophilus, L. gasseri, L. fermentum, L. paracasei and L. plan-
tarum) are considered to have QPS-status (Leuschner et al., 2010; EFSA, 
2011b). However, there exists a highly various range of species-specific natural 
antibiotic resistance among different species and strains of lactobacilli, mostly 
non-transmissible (Mändar et al., 2001; Danielsen and Wind, 2003; Mikelsaar, 
2011). 
The knowledge of the resistance pattern of the probiotic would be useful to 
avoid using strains that carry transferable resistance genes. Plasmid-encoded 
erythromycin, tetracycline and chloramphenicol resistance has been reported in 
lactobacilli (Axelsson et al., 1988; Lin et al., 1996; Gevers et al., 2003).  
Some studies indicate a higher risk of antibiotic resistance transfer than 
previously believed, especially during treatment with antibiotics (Jacobsen et 
al., 2007; Toomey et al., 2009). On the contrary, Egervärn and co-workers 
(2010) have demonstrated that the tetracycline resistance gene from probiotic 
Lactobacillus reuteri was not transferable to bacteria in the GI tract of humans 
(Egervärn et al., 2010).  
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In case there is detected an antibiotic resistance marker in a new probiotic 
Lactobacillus strain, it is necessary to confirm whether the antibiotic resistance 
is of chromosomal origin or it is carried by plasmids and is therefore putatively 
transferable (Saarela et al., 2000; EFSA, 2008; Egervärn et al., 2010). The latter 
plasmid should be deleted. 
 
 
2.6. Functional properties and colonizing potential  
of probiotic lactic acid bacteria 
The functional properties of probiotics include production of antimicrobial 
compounds, suppression of pathogens, expression of antioxidative activity, 
immune stimulation and colonizing potential such as tolerance to acid, bile and 
pancreatin (Saarela et al., 2000; Mikelsaar and Zilmer, 2009). The functional 
requirements of probiotics should be established using in vitro methods and the 
results of these studies should be reflected in controlled human studies. The 
functional properties differ significantly among various Lactobacillus species 
and strains (Annuk et al., 2003; Kõll et al., 2008).  
 
 
2.6.1. Acid, bile and pancreatin tolerance 
To provide health benefits, Lactobacillus strains, which are mostly delivered in 
a food system, must overcome physical and chemical barriers in the GI tract, 
especially acid and bile stress (Del Piano et al., 2006). Probiotics also need to 
possess the ability to survive in products with sufficient numbers during 
production and storage (Songisepp, 2005; Ljungh and Wadstrom, 2006). 
In the stomach and the upper intestine, containing gastric acid and bile, 
bacterial survival under the adverse conditions is attributable primarily to their 
ability to maintain intracellular pH by means of proton-translocating ATPase 
(Bender and Marquis, 1987). Other mechanisms for survival include changes in 
the cell membrane, regulatory mechanisms, metabolic pathways, amino acid 
decarboxylation and heat-shock proteins (Lim et al., 2000; Cotter and Hill, 
2003). 
 
 
2.6.2. Adhesion 
The ability of lactobacilli to adhere to epithelial cells is considered an important 
feature in the process of colonization of the different human ecological niches 
such as the gut and the vagina. Adhesion of lactobacilli to epithelial cells is 
facilitated by several exported proteins (e.g. mucus binding protein, lectin-like 
mannose adhesin, sortase-dependent and other surface layer proteins), carbo-
hydrates and lipoteichoic acid (Lebeer et al., 2008; Sanchez et al., 2008). A 
number of in vitro models (e.g. cell lines Caco-2 and HT-29, immobilised 
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intestinal mucus) have been used to study the adhesion properties of probiotic 
bacteria (Tuomola et al., 1999; Ouwehand and Salminen, 2003; Laparra and 
Sanz, 2009). 
The abilities of lactobacilli to adhere to the intestinal mucosa (e.g. cell lines) 
and the mucus layer may be different. Ouwehand and co-workers have shown 
that adherence of lactobacilli to the intestinal tissue was lower than to the intes-
tinal mucus (Ouwehand et al., 2002). Therefore, it has been suggested to use 
both test models for evaluation of the adhesive properties of lactobacilli. The 
auto-aggregative ability has also been used as an indicator for adhesion (Perez 
et al., 1998; Collado et al., 2008). In a previous study Annuk and coauthors 
showed the importance of the lectin profiles of different Lactobacillus sp. in 
autoaggregating strains, mainly of the L. acidophilus group (Annuk et al., 
2001). 
In vitro results regarding the adherence capacities of lactobacilli are difficult 
to extrapolate to the GI tract situation in vivo, where individual host defense 
systems, competition with the resident microbiota for nutrients and space, 
mucosal shedding, and peristaltic flow, that continuously washes the GI tract 
epithelium, are likely to modify adhesion (Servin, 2004). There is a need for 
complex in vitro and colonization studies to assess the value of in vitro tests. 
 
 
2.6.3. Antimicrobial activity 
Lactobacilli produce a wide range of antibacterial compounds including sugar 
catabolites such as organic acids (e.g. lactic acid and acetic acid); oxygen 
metabolites such as hydrogen peroxide; fat and amino acid metabolites such as 
fatty acids, phenyllactic acid, and OH-phenyllactic acid; proteinaceous com-
pounds such as bacteriocins, other low-molecular-mass peptides, and antifungal 
peptides/proteins and particular compounds such as reuterin and reutericyclin 
(Ouwehand and Vesterlund, 2004). 
Bacteriocins are most often active towards closely related gram-positive 
bacteria, while the producer cells are tolerant to their own bacteriocins (De 
Vuyst and Leroy, 2007). However, activity against gram-negative bacteria, e.g. 
Salmonella, by Lactobacillus bacteriocins or bacteriocin-like substances has 
also been described (Lin et al., 2008). The most common mode of action of 
antimicrobial compounds is the formation of pores in the bacterial membrane, 
but they can also act by prevention of cell-wall synthesis, inhibition of RNA 
synthesis and inhibition of bacterial phospholipases (Sang and Blecha, 2008). 
Production of plantaricins is typical of several L. plantarum strains. Sub-
class IIa includes food-borne pathogens inhibiting bacteriocins, sub-class IIb 
harbours di-peptide bacteriocins of a wide activity range: plantaricin EF and 
plantaricin JK, also plantaricin S (Maldonado et al., 2002). 
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2.6.4. Ability to persist in the gut 
When selecting potential probiotic strains, there arises the question about which 
probiotic strains will survive and transiently colonize the GI tract. Many strains 
currently used as probiotics have a documented ability to survive in the human 
gut and are recovered alive in faeces (Goldin et al., 1992; Mätto et al., 2006; 
Tuohy et al., 2007). 
The isolation of the same strain over time after cessation of consumption 
could then imply persistent colonization. It has been demonstrated in clinical 
trials that probiotic lactobacilli persist in faecal samples for a few days up to a 
week after intake has stopped (Goldin et al., 1992; Saxelin et al., 1995; 
Jacobsen et al., 1999; Mätto et al., 2006). 
 
 
2.6.5. Antioxidative properties 
Lactic acid bacteria (including lactobacilli and bifidobacteria) have demon-
strated antioxidative ability in vitro experiments (Kaizu et al., 1993; Kullisaar et 
al., 2002; Koller et al., 2008; Kaushik et al., 2009). 
The antioxidative properties of lactic acid bacteria include ROS inactivation 
via enzymatic mechanisms (e.g. by a coupled NADH oxidase/reductase system, 
superoxide dismutase) and non-enzymatic mechanisms such as scavenging by 
glutathione system (Kaizu et al., 1993; Kullisaar et al., 2002; Lee et al., 2005). 
The probiotic strain L. fermentum ME-3 contains both glutathione peroxidase 
and glutathione reductase by which the strain can transport GSH from the 
environment and even synthesize it (Kullisaar et al., 2010). GSH is the cellular 
redox buffer acting as a scavenger of free radicals and toxic substances, and 
serving as a co-substrate for detoxification enzymes (Hansen et al., 2009). 
In a mouse model of Salmonella Typhimurium infection, the administered 
antioxidative L. fermentum ME-3 increased total antioxidative activity and the 
glutathione redox value in the intestinal mucosa, which indicates a mani-
festation of antioxidative potential in vivo (Truusalu et al., 2004; Truusalu et al., 
2008; Truusalu et al., 2010). 
A recent study showed that probiotic treatment (L. plantarum HEAL19) with 
polyphenol rich fruit (bilberry) reduced lipid peroxidation in a mouse model of 
intestinal ischemia-reperfusion (Jakesevic et al., 2011). 
 
 
2.7. Assessment of the safety and efficacy  
of probiotics in clinical trials 
The most important proof of probiotic safety and functional efficacy should be 
tested with clinical studies in children, adults and elderly. Intervention studies 
provide stronger evidence than observational studies. Clinical intervention trials 
for probiotic evaluation are divided into four phases: phase 1 (safety), phase 2 
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(efficacy), phase 3 (effectiveness) and phase 4 (surveillance) (FAO/WHO, 
2002; Reid et al., 2003).  
First, phase 1 pilot clinical trials on healthy volunteers to exclude the 
adverse effects of probiotic administration on gut health, and on the biochemical 
and cellular indices of blood, reflecting the proper functions of human organs, 
should be conducted (Reid, 2005; Rijkers et al., 2010). 
It has been suggested, from the healthy human’s perspective, that evaluation 
of tolerance and safety may be based on self-reported questionnaires for 
monitoring symptoms and adverse effects, blood safety parameters and number 
and type of adverse events (Borriello et al., 2003; Vankerckhoven et al., 2008; 
Vlieger et al., 2009; Wind et al., 2010). The tolerance and safe administration of 
probiotics can be evaluated by several measurements, such as measurement of 
body weight or blood pressure, and parameters of haematologic analysis and of 
serum/plasma chemical analysis (liver and renal function indices).  
Next, in efficacy studies (phase 2) the manifestation of the strain’s functional 
properties, either by improving some physiological functions of the host (e.g. 
antimicrobial, metabolic, immunogenic, antioxidative) or by reducing the risk of 
some diseases after the consumption of the probiotic product in large groups of 
volunteers, should be tested.  
There are several designs for probiotic intervention studies: open-label trial, 
double-blind, placebo-controlled trial; and randomised, double-blind, placebo-
controlled crossover trial. Clinical trials for evaluation of the efficacy of pro-
biotics should be randomised and double-blinded.  
For elucidation of the mechanisms of probiotic impact, different study 
designs including non-randomised double-blind placebo controlled or open-
label prospective and cross-sectional studies are also suggested (EFSA, 2011c). 
 
 
2.7.1. Efficacy of antioxidative probiotics in human studies 
Quite a new area of research is the response of host cells and molecules such as 
lipid, proteins and DNA to oxidative damage. Up to now it has caused several 
misunderstandings in evaluation of the clinical efficacy of antioxidative sub-
stances. In our previous studies several markers of oxidative stress and 
antioxidative defence were applied. Namely, the consumption of the probiotic 
L. fermentum ME-3 in fermented goat milk or in probiotic capsules increased 
TAS values in healthy subjects (Kullisaar et al., 2003; Songisepp et al., 2005). 
Also, in patients with mild-to-moderate atopic dermatitis the consumption of L. 
fermentum ME-3 goat milk improved blood antioxidative activity (TAS and 
TAA), GSH levels increased and the ratio GSSG/GSH decreased (Kaur et al., 
2008). 
Recently, the Nutrition, Dietetic and Allergy (NDA) panel was asked by the 
European Food Safety Authority (EFSA) to draft guidance on scientific 
requirements for health claims related to antioxidants, oxidative damage and 
cardiovascular health. The document was not intended to include an exhaustive 
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list of beneficial effects and studies/outcome measures which are acceptable 
(EFSA, 2011a). However, the panel doubted that the overall antioxidant 
capacity of plasma could exert a beneficial effect in humans as required by the 
EC Regulation 1924/2006. Further, they confirmed that the scientific substan-
tiation of health claims on the protection of molecules from oxidative damage 
required at least one appropriate marker of oxidative modification of the target 
molecule assessed in human studies, preferably in combination with other 
marker(s) determined in the same study.  
Measurements of oxidative damage to lipids (i.e. lipid peroxidation) can be 
obtained in vivo by measuring oxidised LDL particles in blood. Several other 
proposed methods, include lipid peroxides, HDL-associated paraoxonases and 
conjugated dienes, could be used as supportive evidence if used in the same 
study. 
Concerning protection from oxidative damage, there are no clinical inter-
vention trials studying the impact of antioxidative lactic acid bacteria combined 
with a prebiotic on host serum and on cell antioxidative activity, particularly, on 
the amount and state of lipid molecules in healthy volunteers.  
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3. THE AIMS OF THE STUDY 
The general goals of the research were: 
 to evaluate the functional properties of some commercial probiotics; 
 to compare the required properties of probiotic strains obtained in in vitro 
and animal experiments with their impact on the health indices of the human 
organism after consumption. 
 
The aims of the present study were: 
1)  To evaluate the in vitro antagonistic activity of some commercial probiotic 
Lactobacillus and Bifidobacterium strains against various gastric, entero- 
and urinary pathogens residing in distinct niches throughout the GI tract and 
to assess the antioxidative activity of the above mentioned probiotic strains. 
2)  To establish the efficacy of consumption of a synbiotic product containing 
selected commercial antimicrobial and antioxidative strains (L. fermentum 
ME-3, L. paracasei 8700:2, B. longum 46) and raftilose P95 in lowering the 
oxidative stress markers of blood (oxLDL, BDC-LDL) in healthy persons. 
3)  To screen the putative probiotic Lactobacillus strains of the intestinal tract, 
deposited in the Human Microbiota Biobank of the Department of Micro-
biology of the University of Tartu, for their colonizing potential using in 
vitro tests mimicking the GI tract conditions. 
4)  To assess the safety of the probiotic L. plantarum TENSIA (DSM 21380) 
and of previously selected six Lactobacillus strains using in vitro and animal 
experiments. 
5)  To evaluate the survival and persistence of selected putative probiotic 
candidates and of the probiotic strain TENSIA in the GI tract of healthy 
volunteers after consumption. 
6)  To assess the safety of consumption of the probiotic strain L. plantarum 
TENSIA and five capsulated putative probiotic strains in healthy volunteers. 
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4. MATERIAL AND METHODS 
An overview of the material and methods used in this study is presented in 
Table 2 and, additionally, a detailed description is available in the following 
section. 
 
Table 2. Study subjects, experimental animals, microbial strains and performed investi-
gations. 
 Study design and 
description 
Presented 
in papers 
a) Probiotic strains 
L. rhamnosus GG (ATCC 53103) 
L. fermentum ME-3 (DSM 14241) 
L. acidophilus La5  
L. plantarum 299v (DSM 9843) 
L. paracasei 8700:2 (DSM 13434) 
B. lactis Bb12 
B. longum 46 (DSM 14583) 
In vitro assessment 
of functional 
properties 
(antagonistic and 
antioxidative 
activity) of 
commercial 
probiotic 
lactobacilli and 
bifidobacteria  
I 
b) pathogenic bacteria 
E. coli (ATCC 700336, pyelonephritic strain) 
E. coli (ATCC 700414, cystitic strain) 
Salmonella enterica ssp. enterica (ATCC 
13076) 
Shigella sonnei (ATCC 25931) 
H. pylori (NCTC 11637) 
C. difficile (VPI 10463) 
53 healthy adult volunteers: 41 female + 12 male, 
H. pylori-positive (n=28) and H. pylori-negative 
persons (n=25) 
RDBPCCOT 
(Efficacy study) 
Evaluation of 
antioxidative 
activity 
II, present 
study 
Selected 6 putative probiotic Lactobacillus 
strains from Biobank 
L. gasseri 177 
L. gasseri E16B7 
L. acidophilus 821-3 
L. paracasei 317 
L. fermentum 338-1-1 
L. paracasei 1-4-2A 
Probiotic L. plantarum TENSIA (DSM 
21380) 
In vitro screening 
of colonizing 
potential (auto-
aggregation 
ability, acid, bile 
and pancreatin 
tolerance) and 
safety in vitro 
 
III 
 
 
 
 
Pathogens (controls for haemolytic activity 
testing) 
Staphylococcus aureus (ATCC 25923) 
Streptococcus pyogenes (ATCC 19615) 
Streptococcus pyogenes (human clinical 
isolate) 
Testing of 
haemolytic activity 
of lactobacilli  
III 
 
Study subjects / Objectives 
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Table 2. Continuation 
description 
Presented 
in papers 
BALBc mice (n=10) / NIH mice (n=10)  Safety assessment in vivo III, V 
15 healthy adult volunteers (9 female + 6 
male) 
OLT 
Assessment of 
survival/persistence and 
safety of the selected 5 
strains in human trial 
IV 
18 healthy over 60 year-old persons  
(17 female + 1 male) 
DBPCT 
Assessment of 
survival/persistence and 
safety of L. plantarum 
TENSIA 
V, VI 
12 healthy adult volunteers (7 female + 5 
male) 
DBPCT 
Assessment of 
survival/persistence and 
safety of L. plantarum 
TENSIA 
V, VI 
DBPCT – double-blind, placebo-controlled trial; RDBPCCOT – randomised, double-blind, 
placebo-controlled crossover trial; OLT – open-label trial 
 
Altogether 98 healthy adults without known health problems completed the 
clinical trials of this study.  
Commercially available probiotic Lactobacillus sp (n=5) and Bifido-
bacterium sp (n=2) strains, intestinal isolates of different species (n=6) of 
Estonian and Swedish 1–2 yr old infants, a patented Lactobacillus strain 
(Lactobacillus plantarum TENSIA, DSM 21380), and 9 pathogenic reference 
strains were used in vitro experiments. 
 
 
4.1. Microbial strains tested in vitro 
4.1.1. Probiotic lactobacilli and bifidobacteria strains 
(Papers I, II) 
The following well-known probiotic bacteria (Figure 2) were selected: 
L. rhamnosus GG (ATCC 53103; Valio, Helsinki, Finland), L. fermentum ME-3 
(DSM 14241, University of Tartu, Estonia), L. acidophilus La5 (Chr. Hansen, 
Hørsholm, Denmark), L. plantarum 299v (DSM 9843, Probi, Lund, Sweden), 
L. paracasei 8700:2 (DSM 13434; Probi, Lund, Sweden), B. lactis Bb12 (Chr. 
Hansen, Hørsholm, Denmark) and B. longum 46 (DSM 14583, University of 
Turku, Finland) were used in the present study (Table 2, paper I). These six 
commercial probiotic strains (except L. fermentum ME-3) were obtained from 
the culture collection of the University of Turku (partner of the 5th Framework 
Programs “Microfunction”). 
 Study design and Study subjects / Objectives 
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Lactobacilli strains were grown on MRS agar and bifidobacteria were grown 
on Wilkins-Chalgren agar with 7% horse blood. The strains were Gram stained 
and examined with light microscopy for cell morphology under 1000X magni-
fication to reveal differences in cell morphology (Figure 2a). Molecular 
fingerprints of the Lactobacillus strains are depicted in Figure 2b. Species 
identification was confirmed by comparison of the 16S-23S rRNA gene spacer 
regions with those of the reference strains.  
 
Figure 2a. Colony and cell morphology of the tested commercial probiotic strains. 
 
 
1, L. paracasei 8700:2; L. paracasei spp paracasei DSM 20020; 3, L. paracasei DSM 5622; 4, L. 
plantarum 299v; 5, L. plantarum ATCC 14917; 6, L. acidophilus La5; 7, L. acidophilus ATCC 
4356; 8, L. fermentum ME-3; 9, L. fermentum ATCC 14931; 10, L. rhamnosus GG; 11, L. 
rhamnosus ATCC 14931; 100 bp DNA ladder. 
The Lactobacillus species-specific ITS-PCR was carried out by using primers 16S-1500F and 
23S-32R (DNA Technology AS) targeted on the 16S-23S rRNA intergenic spacer region. 
 
Figure 2b. Molecular fingerprints of commercial Lactobacillus strains. Detected by 
applying ITS-PCR (Štšepetova et al., 2002). 
10
38 
4.1.2. Putative probiotic strains 
(Papers III, IV) 
Hundreds of Lactobacillus strains were isolated from faecal samples of 1 to 2-
year-old Estonian and Swedish children in a joint Estonian-Swedish project for 
evaluation of development of allergy (Mikelsaar et al., 2002). In the present 
study six strains were used according to the results of in vitro screening (colo-
nizing potential, potential of haemolytic activity and antibiotic susceptibility 
patterns).  
 
 
4.1.3. Probiotic L. plantarum TENSIA 
(Papers III, V, VI) 
Lactobacillus plantarum TENSIA was isolated from a faecal sample of a 
healthy Estonian child during a comparative study of the microbiota of Estonian 
and Swedish children (Mikelsaar et al., 2002). L. plantarum TENSIA belongs to 
the Bio-Competence Centre of Healthy Dairy Products LCC, Estonia. 
L. plantarum TENSIA is deposited in Deutsche Sammlung von Mikroorga-
nismen and Zellkulturen GmbH-DSMZ under number DSM 21380. Probiotic 
cheese comprising L. plantarum TENSIA in semi-hard Edam-type cheese has 
been developed in cooperation with the Dairy Cooperative E-Piim. The 
L. plantarum TENSIA maintained good viability in probiotic cheese (Rätsep et 
al., 2009). 
 
 
4.1.4. Pathogenic strains 
(Papers I, III) 
The pathogenic target bacteria E. coli ATCC 700336 (pyelonephritic strain), 
E. coli ATCC 700414 (cystitic strain), Salmonella enterica ssp. enterica ATCC 
13076, Shigella sonnei ATCC 25931, H. pylori NCTC 11637, C. difficile VPI 
10463 were used as the target bacteria in the antagonistic activity experiments 
(Table 2).  
The gram-positive cocci Staphylococcus aureus (ATCC 25923) and two 
Streptococcus pyogenes strains (ATCC 19615 and a human clinical isolate) 
were used as the positive controls in testing haemolytic activity of putative 
probiotic bacteria. 
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4.2. Characterization of putative probiotic strains 
(Paper III) 
4.2.1. Testing of auto-aggregation ability 
The auto-aggregation ability of putative probiotic lactobacilli and of the 
probiotic L. plantarum TENSIA was determined as described by Pascual et al. 
(Pascual et al., 2008) with certain modifications. Briefly, lactobacilli were 
grown for 48h at 37C on MRS agar (Oxoid, Basingstoke, United Kingdom) 
plates in a microaerobic environment (10% CO2). A loopful (10 l) of culture 
was suspended on a glass microscope slide in 1 ml of 0.9% saline solution (pH 
6.7) to a final concentration corresponded to McFarland Nephelometer Standard 
3. Auto-aggregation was determined as the ability to form aggregates (clearly 
visible sand-like particles) within 2 min at room temperature. The results were 
expressed as: score 0 – no auto-aggregation, score 1 – intermediate auto-ag-
gregation (presence of some flakes), and score 2 – strong auto-aggregation. 
 
 
4.2.2. Testing of acid, bile and pancreatin tolerance 
(Paper III) 
The effect of low pH, bile, and pancreatin on the survival of lactobacilli was 
examined in microwell plates (Costar 96 Well Cell Culture Clusters, Myriad 
Industries, San Diego, CA). MRS broth (Oxoid) was adjusted to a pH range 
between pH 5.0 and pH 2.0 to test acid tolerance and contained oxgall (2% w/v) 
(Sigma, Steinheim, Germany) and/or pancreatin (0.5% w/v) (Sigma, Steinheim, 
Germany) to test bile and pancreatin tolerance. Each 180-l volume of adjusted 
and nonadjusted MRS broth (as control; pH 6.0) was inoculated with 20 l 
lactobacilli suspension (McFarland 1.0 turbidity standard) and incubated in a 
microaerobic environment at 37 C for 4 h.  
The number of cells in the suspension of lactobacilli and the number of 
surviving cells following incubation in pH-, bile- and pancreatin-adjusted media 
was determined by plating 100 l of tenfold serially diluted sample onto MRS 
agar (Jacobsen et al., 1999; Kõll et al., 2008). Strains with viable cell counts 
equal to viable counts before incubation in pH-, bile- and pancreatin adjusted 
media were considered as resistant to a particular pH, bile and pancreatin 
concentration. 
The colonizing potential (auto-aggregation, tolerance to acid, bile and pan-
creatin) of putative probiotics were determined by Piret Kõll. 
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4.2.3. Testing of haemolytic activity  
(Paper III) 
A single line of lactobacilli culture (grown in MRS broth for 48h) was streaked 
onto blood agar plates containing either human or horse blood. The haemolytic 
activity of putative probiotics was verified visually after 24h and 48h of 
incubation in aerobic, microaerobic (10% CO2) and anaerobic (90% N2, 5% 
CO2, 5% H2) environments. The blood agar plates were examined for signs of 
β-haemolysis (clear zones around colonies), α-haemolysis (green halo around 
colonies) or γ-haemolysis (no zones around colonies) (Pfaller et al., 2007).  
The Staphylococcus aureus strain (ATCC 25923) and two Streptococcus 
pyogenes strains (ATCC 19615 and a human clinical isolate, respectively) were 
used as the positive controls.  
 
 
4.2.4. Testing of antibiotic susceptibility 
(Papers III, V, VI) 
Minimum inhibitory concentrations (MICs) of ampicillin, vancomycin, gen-
tamicin, erythromycin, tetracycline, chloramphenicol, ciprofloxacin, rifampicin 
and trimethoprim-sulfamethoxazole were determined by the E-test method as 
described by the manufacturer. 
Wilkins-Chalgren (Oxoid, Basingstoke, United Kingdom) agar plates with 
5% horse blood, E-test antibiotic strips (AB Biodisk, Solna, Sweden) and 48h of 
incubation at 37ºC in an anaerobic glove chamber were used. The MIC (mini-
mal inhibitory concentration) was determined according to the Clinical and 
Laboratory Standards Institute (CLSI) (former National Committee for Clinical 
Laboratory Standards (NCCLS)) guidelines (Jorgensen and Turnidge, 2003; 
CLSI, 2006). 
Strains with MICs equal and higher than the breakpoints (µg/ml) were 
considered as resistant. More recently, EFSA proposed microbial breakpoints 
for lactobacilli at the genus and species levels, and for different fermentation 
types (OHOL, FHEL, OHEL) of lactobacilli (EFSA, 2008). 
 
 
4.3. Total anti-oxidative activity 
(Paper I) 
The total antioxidative activity (TAA) and the total antioxidative status (TAS) 
of seven commercial probiotic bacteria were assessed. Testing of the anti-
oxidative activity of the bacteria was performed by Tiiu Kullisaar from the 
Department of Biochemistry. 
TAA was measured using the linolenic acid test (LA-test) (Kullisaar et al., 
2002). Lactobacilli were grown in MRS broth under microaerobic conditions 
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and bifidobacteria in MRS broth supplemented with cysteine in an anaerobic 
environment for 48h. 
Probiotic bacteria were pelleted by centrifugation (10 000 g for 10 min), 
washed twice and re-suspended in isotonic saline at 4C. The density of the 
suspension was adjusted to 109 CFU/ml using an absorbance of 1.1 at 600 nm. 
TAA was expressed as the percentage of inhibition of the peroxidation of the 
linolenic acid standard by the sample, which predominantly reflects the anti-
oxidative status of the lipid fraction. 
The TAS of the bacteria was assessed using a commercially available kit 
(TAS, Randox Laboratories Ltd. Ardmore, UK) (Kullisaar et al., 2003). A 
water-soluble vitamin E (Trolox) served as the standard. This method is based 
on inhibition of the absorbance of the ferrylmyoglobin radicals of 2,2’-azinobis-
ethylbenzothiazoline 6-sulfonate (ABTS+) generated by the activation of 
metmyoglobin peroxidise with H2O2, and indicates the anti-oxidative activity in 
water fractions.  
The total anti-oxidative values of the probiotic bacteria were considered high 
if TAA was >20% and TAS > 0.1 mmol/l.  
 
 
4.4. Antagonistic activities of commercial probiotics 
(Paper I) 
The antagonistic activity of commercial probiotic strains (L. rhamnosus GG, L. 
fermentum ME-3, L. acidophilus La5, L. plantarum 299v, L. paracasei 8700:2, 
B. lactis Bb12, B. longum 46) against entero- and uropathogens was assessed 
using solid and liquid media under microaerobic and anaerobic conditions.  
The antimicrobial activity of the probiotic strain L. plantarum TENSIA 
against entero- and uropathogens was detected in microaerobic conditions on 
solid media. 
 
 
4.4.1. Antimicrobial activity of lactobacilli and  
bifidobacteria on agar plates 
Briefly, prior to final inoculation, the lactobacilli were pre-cultivated three times 
in the respective environment. Bifidobacteria, as strict anaerobes, were grown 
only in an anaerobic environment. 
The antimicrobial activity of probiotic lactobacilli and bifidobacteria against 
selected target bacteria was assessed using a streak line method. The following 
media were used: modified MRS medium (MRS medium without tri-
ammonium-citrate and sodium-acetate; pH 7.2) for lactobacilli, Wilkins-
Chalgren agar with 7% horse blood for bifidobacteria and C. difficile, and 
Columbia Agar Base supplemented with 7% horse blood and 1% Vitox for 
H. pylori. 
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Lactobacilli and bifidobacteria were seeded in the middle of the agar plate 
using a 10 l loop. Following the incubation in a microaerobic/anaerobic 
environment at 37C for 48h for lactobacilli, or in an anaerobic environment for 
bifidobacteria, growth was inactivated with chloroform gas which was used for 
2h. The following target bacteria were tested: E. coli, Salmonella enterica 
subspecies enterica and S. sonnei grown in peptone water for 18h (turbidity 109 
CFU/ml), a H. pylori suspension in Brucella broth (BBL, Cockeysville, MD, 
USA) adjusted to McFarland density of 3–4, and a C. difficile suspension in 
saline adjusted to a McFarland density of 1. The target bacteria were seeded 
using a 1 l loop, in duplicate, perpendicular to the streak line of lactobacilli 
and bifidobacteria on the respective media as described above, and were 
incubated at 37C. E. coli, Salmonella enterica subspecies enterica and S. 
sonnei were incubated in aerobic environment for 18h, H. pylori was grown in a 
microaerobic environment for 3 days, and C. difficile was incubated anaerobi-
cally for 2 days. 
The antagonistic activity of lactobacilli and bifidobacteria was estimated as 
the width of the inhibition zone (mm) of the target bacteria extending from the 
culture line of probiotic bacteria (Mikelsaar et al., 1987; Annuk et al., 2003). 
The inhibitory effect of the lactobacilli and bifidobacteria was ranked as high 
(>25 mm), moderate (13–25 mm) and low (0–12 mm).  
 
 
4.4.2. Antimicrobial activity of probiotic lactobacilli and 
bifidobacteria in broth 
Probiotic bacteria were pre-incubated as described above. The strains of E. coli, 
Salmonella enterica subspecies enterica or S. sonnei in equal aliquots were co-
incubated with the suspensions of lactobacilli or bifidobacteria in isotonic saline 
(109 CFU/ml) at 37C for 24h under microaerobic and/or anaerobic conditions. 
Thereafter, the number of colony forming units (CFU/ml) of the target gram-
negative bacteria was semi-quantitatively determined on peptone agar (Gould, 
1965).  
Inhibition of pathogen growth was calculated by subtracting the number of 
target bacteria remaining in the co-incubation tube from the number in the 
control tube with only target bacteria (Annuk et al., 2003). The result was 
expressed as log10 CFU/ml. The values of inhibition of growth of pathogens by 
probiotics in liquid media were ranked as high, moderate and low (decrease by 
5.9–6.5, 3.4–5.8 and 0.6–3.2 log10 CFU/ml, respectively). 
 
 
4.4.3. Antagonistic activity between probiotic strains and 
putative probiotic lactobacilli strains 
The antimicrobial activity of probiotic lactobacilli, putative probiotic lacto-
bacilli and probiotic bifidobacteria against selected target lactobacilli or 
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bifidobacteria was assessed using a streak line method as described above (pre-
sent study). 
Briefly, lactobacilli were cultivated in microaerobic condition and bifido-
bacteria, as strict anaerobes, were grown only in an anaerobic environment. The 
following media were used: modified MRS medium (MRS medium without 
triammonium-citrate and sodium-acetate; pH 7.2) for lactobacilli, Wilkins-
Chalgren agar with 7% horse blood for bifidobacteria. Lactobacilli and bifido-
bacteria were seeded in the middle of the agar plate using a 10 l loop. Fol-
lowing the incubation in a microaerobic/anaerobic environment at 37C for 48h 
for lactobacilli, or in an anaerobic environment for bifidobacteria, growth was 
inactivated with chloroform gas during 2h. The target bacteria (lactobacilli or 
bifidobacteria) were seeded using a 1 l loop, in duplicate, perpendicular to the 
streak line of lactobacilli and bifidobacteria on the respective media and 
environment as described above, and were incubated at 37C for 2 days. 
The antagonistic activity of lactobacilli and bifidobacteria was estimated as 
the width of the inhibition zone (mm) of the target bacteria extending from the 
culture line of the bacteria (Mikelsaar et al., 1987; Annuk et al., 2003). 
 
 
4.5. Determination of organic acids 
(Papers I, V) 
The production of organic acids (acetic acid, lactic acid, succinic acid) of 
probiotic strains (L. rhamnosus GG, L. fermentum ME-3, L. acidophilus La5, L. 
plantarum 299v, L. paracasei 8700:2, B. lactis Bb12, B. longum 46) and of the 
probiotic L. plantarum TENSIA was performed using gas chromatographic 
analyses in cooperation with Ms Jelena Stsepetova. 
The production of organic acids was estimated by gas chromatography as 
described by Holdeman et al. (1977). The gas chromatograph (Hewlett-Packard 
model 6890) was equipped with a hydrogen flame ionization detector and an 
auto sampler (model 7683). The HP Chemical Station for the GC System (A.06 
revision) was used. Analyses were performed following the cultivation of lacto-
bacilli in microaerobic and anaerobic environments in modified MRS broth for 
24h and cultivation of bifidobacteria under anaerobic conditions in MRS broth 
supplemented with cysteine for 24h. 
 
 
4.6. Faecal recovery of Lactobacillus strains 
(Papers IV, V) 
The survival and persistence of consumed putative probiotic strains and the 
probiotic L. plantarum TENSIA were investigated in faecal samples of healthy 
adults and healthy persons over 60 years of age. The impact of the consumption 
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of the above mentioned strains on the counts of indigenous lactobacilli was also 
measured.  
Survival of Lactobacillus strains indicates their ability to survive passage 
through the GI tract during consumption. Persistence shows their ability to 
maintain viability in the GI tract after discontinuation of consumption of the 
probiotic product. 
 
 
4.6.1. Isolation and preliminary  
identification of Lactobacillus spp 
The counts of total faecal Lactobacillus isolates of indigenous lactobacilli, and 
of the Lactobacillus strains consumed during the trials were evaluated in faecal 
samples by a conventional cultivation method. Serial dilutions (10–2– 10–9) of 
weighed faecal samples were prepared with sterile saline and 0.05 ml aliquots 
was seeded onto MRS and Rogosa agar media (Mikelsaar et al., 2002; 
Songisepp et al., 2005). The plates were incubated at 37°C for 3 days mi-
croaerobically in a 10% CO2 environment (incubator IG 150, Jouan, France).  
Provisional identification of lactobacilli isolates was based on gram-positive 
rod-shaped nonsporing cell morphology and negative catalase reaction. Further 
identification included biochemical characteristics and/or API 50 CHL 
(BioMérieux, Marcy-l’Etoile, France). Isolates were provisionally identified as 
lactobacilli and were further analysed for fermentation type. The ability of 
isolates to grow in MRS broth for 24h in a 10% CO2 environment at 15°C and 
37°C and to produce gas in MRS agar with 1% glucose was also assessed. The 
fermentation of glucose without gas production, growth at 37°C and no growth 
at 15°C identifies obligate homofermentative lactobacilli (OHOL); growth both 
at 15°C and 37°C without gas production is characteristic of facultative hetero-
fermentative lactobacilli (FHEL), whereas gas production at 37°C and variable 
growth at 15°C are characteristic of obligate heterofermentative lactobacilli 
(OHEL). The count of Lactobacillus species was expressed in log10 colony 
forming units (CFU) per gram of faeces (log10 CFU/g). The detection level of 
lactobacilli was 3.0 log10 CFU/g faeces. Lactobacilli were considered indige-
nous if they were different from consumed strains according to molecular 
typing results. 
 
 
4.6.2. Detection of survival and persistence  
of consumed putative probiotic strains 
The intestinal survival and persistence of the probiotic TENSIA were detected 
in faecal samples of 30 healthy volunteers after consumption of probiotic 
cheese. The intestinal survival and persistence of 4 putative probiotic strains, L. 
gasseri 177, L. gasseri E16B7, L. paracasei 317 and L. fermentum 338-1-1, 
were investigated in 9 persons and the intestinal survival and persistence of the 
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selected strain L. acidophilus 821-3, in 14 persons after consumption of 
probiotic capsules. 
The intestinal survival and persistence of ingested L. plantarum TENSIA 
were detected by conventional cultivation and further typing with specific 
primers for arbitrarily primed PCR (AP-PCR). 5 putative probiotic strains (177, 
E16B7, 317, 338-1-1, 821-3) consumed in a mixture were identified applying 
the same methods. In addition, for detection of the persistence of the L. 
acidophilus 821-3 a strain specific real-time PCR was developed in collabo-
ration with the Professor Lennart Hammarström’s group, Department of Labo-
ratory Medicine, Karolinska Institute, Sweden. 
 
4.6.2.1. Molecular methods 
4.6.2.1.1. AP-PCR typing 
Putative Lactobacillus isolates were typed by AP-PCR. Pure cultures were culti-
vated on MRS agar microaerobically for 24h at 37°C in 10% CO2. Genomic 
DNA was extracted with the QIAamp DNA Mini Kit 50 (QIAGEN GmbH., 
Hilden, Germany) according to the manufacturers’ instructions. AP-PCR typing 
was performed using three primers: ERIC1R (5’-ATGTAAGCTCCTGGGG-
ATTCAC-3’), ERIC2 (5’-AAGTAAGTGACTGGGGTGAGCG-3') and Hay-
ford primer (5’-ACGCGCCCT-3’) (DNA Technology A/S, Aarhus, Denmark) 
as described previously (Zhong et al., 1998; Alander et al., 1999; Hayford et al., 
1999). 
The PCR products were resolved by electrophoresis on a 2% agarose gel 
containing ethidium bromide (0.1 μl/ml) in the Tris/acetic acid/EDTA (TAE) 
electrophoresis buffer (Bio-Rad Laboratories, Hercules, USA) at a constant 
voltage of 100 V. A 1 kb ladder (Fermentas, Vilnius, Lithuania) was used as the 
marker. The banding patterns of the isolates were visualized with UV light and 
compared with those of the consumed Lactobacillus strains. 
 
4.6.2.1.2. PCR-DGGE 
The DNA of faecal samples was extracted using QIAamp DNA Stool Mini Kit 
(QIAGEN GmbH., Hilden, Germany). The amount of DNA was determined 
visually after electrophoresis on a 1.2% agarose gel containing ethidium 
bromide. To investigate the microbiota of the Lactobacillus-specific GI tract 
PCR was performed using the 16S rDNA primers Univ-515r-GC (5’-CGCCG-
GGGGCGCGCCCCGGGCGGGGCGGGGGCACGGGGGGATCGTATTACC
GCGGCTGGCA-3’) and Lab-0159f (5’-GGAAACAGRTGCTAATACCG-3’). 
Nested PCR was performed with these primers on previously generated 
products from amplification with 7f (AGAGTTTGATCTACTGGCTCAG) and 
Lab677-r (5’- CACCGCTACACATGGAG-3’) (Heilig et al., 2002).  
PCR-DGGE and AP-PCR were performed by Jelena Stsepetova. 
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4.6.2.1.3. Real-time PCR 
Total genomic DNA from faecal samples was extracted by the QIAamp DNA 
Stool Minikit (QIAGEN GmbH., Hilden, Germany). Quantification of the L. 
acidophilus 821-3 strain, the L. acidophilus species and total lactobacilli in 
faecal samples was performed by real-time PCR using ABI Prism 7300 
(Applied Biosystems, USA). The detailed experimental procedure, protocol, 
strain-specific primers and a Taqman-MGB are described in paper IV. 
Quantification of the L. plantarum TENSIA strain in faecal samples was per-
formed by real-time PCR using ABI Prism 7500 (Applied Biosystems, USA). 
This analysis was done by Eerik Jõgi from the Institute of Technology of the 
University of Tartu. In order to identify a specific genomic sequence for L. 
plantarum TENSIA, oligonucleotides were designed between the conserved 
regions (114415-115632) of the L. plantarum strain WCFS1 complete genome 
(Genbank accession no. AL935255). Using L. plantarum TENSIA genomic 
DNA as the template and the primers tensia1 (5’-GTTAAGGTTTGCAAC-
AGGTC-3’) and tensia2 (5’-GACAATACTAGCCCAAGCTG-3’) 750bp PCR 
products were amplified.  
Amplified fragments were cloned with InsTACloneTM PCR Cloning Kit 
(Fermentas, Vilnius, Lithuania) to pUC57/T vector and transformed to com-
petent E. coli DH5α cells. Clones with inserts were sequenced (BigDye® 
Terminator v3.1 Cycle Sequencing Kit, Applied Biosystems). The sequenced 
750 bp insert (plasmid pUC57/T TEN) a contained partial sequence of the 
phospho-2-dehydro-3-deoxyheptonate aldolase gene. This sequence was used as 
the target for real-time PCR primers. 
The primers for real-time PCR were designed with the web-based program 
Primer3 (http://frodo.wi.mit.edu/primer3). The resulting primers tensiaRT31 
(5’-AACGCAAGCTTTATCCGATG-3’) and tensia RT32 (5’-TGTTAAGGTT-
TGCAACAGGTCA-3’) reaction conditions were tested by regular PCR. The 
specificity of primers was tested by PCR using 6 different L. plantarum strains. 
The real-time PCR reaction mixture (25 µl) contained 5 µl 5xHOT FIREPol® 
EvaGreen® qPCR mix (high ROX) (Solis BioDyne, Tartu, Estonia), 20 pmol 
(each) specific primers and 2.5 µl of template DNA. The amplification program 
consisted of one cycle of 94°C for 5 min, followed by 40 cycles of 94°C for 
20 s, 60°C for 60 s. The fluorescent product was detected at the last step of each 
cycle. Following amplification, melting temperature analysis of PCR products 
was performed to determine the specificity of the PCR. The melting curves were 
obtained by slow heating at 0.2°C/s increments from 60 to 99°C, with 
continuous fluorescence collection. Standard curves were obtained using ten-
fold dilutions of plasmid pUC57/T TEN containing the corresponding amplicon 
ranging from 105 to 10 copies. 
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4.7. Safety testing of putative probiotics  
in animal models 
(Papers III, V, VI) 
In order to determine the safety of consumption of the probiotic L. plantarum 
TENSIA and six putative probiotic lactobacilli in vivo, two animal trials were 
performed in collaboration with Kai Truusalu and Imbi Smidt. 
To determine the safety of the probiotic L. plantarum TENSIA, 10 NIH line 
mice were given the commercial diet R-70 (Lactamin, Sweden) and tap water 
ad libitum and the amount of 50 g of cheese was added per cage daily. The 
average consumption of cheese per mouse per day was calculated after the 
leftover cheese was weighed. Ten mice out of twenty belonged to the test group 
fed with probiotic cheese containing L. plantarum TENSIA in concentration of 
9.6 log10 CFU/g for 30 consecutive days. The control group was fed with the 
same amount of regular cheese without added lactobacilli. Faeces for lacto-
bacilli counts were sampled on days 0, 3, 10, 15, 20 and 30. At the end of the 
trial autopsy was performed. The mice were sacrificed by cervical dislocation 
on day 30 and samples for microbiological analyses were collected. Heart blood 
(10 µl), homogenized tissue of the liver, and spleen were tested for possible 
translocation of the gut microbiota. For detection of L. plantarum TENSIA, 
MRS and blood agar were used. The samples of the small intestine and large 
intestine for lactobacilli counts were plated onto MRS and blood agar (Oxoid, 
UK). After 48h of incubation in a microaerobic environment (MRS plates), 
colonies were enumerated. The Lactobacillus spp. were identified according to 
Gram staining, colony and cell morphology, negative catalase reaction and 
carbohydrate fermentation patterns. Changes in lactobacilli counts in the ileum 
and colon were estimated by microbiological methods and PCR-DGGE. For 
histological analysis, tissue sections of the liver, spleen, kidney and lungs of the 
sacrificed mice were fixed in 10% of formaldehyde and embedded in paraffin. 
The samples were stained with haematoxylin and eosin, and by using van 
Gieson method. Alterative and inflammatory changes in the tissues were 
evaluated. 
To determine the safety of six putative probiotic lactobacilli, a mixture of six 
Lactobacillus strains (L. acidophilus 821-3, L. gasseri E16B7, L. gasseri 177, L. 
paracasei 317, L. paracasei 1-4-2A and L. fermentum 338-1-1 (each strain in a 
concentration of 107 CFU per day) in drinking water was administered to 
10 BALB/c mice (Scanbur BK AB, Sweden) for five consecutive days. Until 
cessation of the trial on day 15, the mice were fed with the commercial diet  
R-70 (Lactamin, Sweden). Five randomly selected mice were sacrificed on day 
5, and the other five mice, on day 15. Samples for histological and micro-
biological analyses were collected.  
Throughout both trials, the animals’ activity, behaviour and general health 
were estimated daily. Namely, changes in the behaviour, coat texture, physical 
activity, and general health of animals but also changes in body weight, and 
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related changes in food and water consumption were observed according to 
OECD Guidance 2000 (OECD, 2000). All animal experiments were conducted 
under a protocol approved by the Ethics Committee on Animal Experiments of 
the Ministry of Agriculture of Estonia (protocol numbers 67/09.11.2006, 
50/07.02.2006). 
 
 
4.8. Clinical trials 
(Papers II, IV, V, VI) 
4.8.1. Ethics and study design 
All trials’ protocols were approved by the Ethics Committee of the University 
of Tartu. All trials were registered in Current Controlled Trials (ISRCTN 
43435738, ISRCTN30946841, ISRCTN38739209 and ISRCTN45791894). 
The present PhD study includes four clinical trials: a randomised double-
blind placebo-controlled trial, two double-blind placebo controlled trials and an 
open-label trial. The expected primary outcomes of the clinical trials are 
presented in Table 3. 
The randomisation list for the synbiotic trial (RDBPCCOT) was generated 
by a researcher who was not involved in recruitment or study visits and research 
(PhD student Piret Kõll). Sealed envelopes contained a study code number that 
corresponded to a particular treatment period (synbiotic or placebo period). The 
investigators and participants of the study were blinded to the randomisation 
code until all data were analysed. Volunteers were allocated to receive a 
synbiotic or a placebo for 3 weeks and after a 2-week washout period the volun-
teers were crossed over to another 3 weeks of placebo or synbiotic admini-
stration. 
All participants in the DBPC probiotic trials received a probiotic cheese 
comprising L. plantarum TENSIA first for three weeks and the control cheese 
for another three weeks after a 2-week washout. The investigators and 
participants of study were blinded to the randomisation until all data were 
analysed. 
In the open-label trial (OLT) for assessment of the safety, survival and per-
sistence of putative probiotic strains, the participants consumed capsules con-
taining lactobacilli for 5 days in two phases of the study (Table 4). Investigators 
and participants of the study were not blinded. 
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Table 3. Registration numbers and primary outcomes of performed clinical trials. 
Study design 
No of registration Primary outcome 
RDBPCCOT 
(paper II) 
ISRCTN43435738 
Effect of synbiotic intake on health indices, biochemical 
markers (including oxidative stress related markers) and faecal 
microflora. 
OLT 
(paper IV) 
ISRCTN30946841 
Safety of consumption of putative probiotic lactobacilli and 
detection of the best colonizer from among the five tested 
Lactobacillus strains in the two phases of trial. 
DBPCT 
(paper V) 
ISRCTN38739209 
acronym: TE1 
Safety of consumption of probiotic cheese comprising 
Lactobacillus plantarum in healthy adults and survival of the 
probiotic strain in gastrointestinal tract and its effect on faecal 
lactoflora. 
DBPCT 
(paper V) 
ISRCTN45791894 
acronym: ELD 
Safety of consumption of probiotic cheese comprising 
Lactobacillus plantarum in over 60-year-old subjects and 
survival of the probiotic strain in gastrointestinal tract and its 
effect on faecal lactoflora. 
 
 
4.8.2. Study population   
Study population involved persons who volunteered to participate, belonged to 
different age groups (adult and/or over 60 years) and considered themselves 
healthy. Participants were asked to maintain their normal diet but refrain from 
the consumption of probiotic products. All participants signed the written 
informed consent and were informed that they could withdraw from the study at 
any time.  
Specific descriptions of all clinical trials are listed in Table 4. 
 
 
4.8.3. Inclusion and exclusion criteria for trials 
Inclusion criteria for selection of the subjects for all trials were: a desire to 
participate, appropriate age (over 18 years old), and without known health 
problems. Exclusion criteria included a history of gastrointestinal disease, food 
allergy and acute infection, cardiovascular diseases, use of any antimicrobial 
agent within the preceding month or use of any regular concomitant medication 
including non-steroidal anti-inflammatory drugs and antioxidant vitamins, 
pregnancy and breastfeeding. The withdrawal criteria from the trials included 
acute infections during the study, unwillingness to proceed with the study or 
relocation to new area. 
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4.8.4. Probiotic strains and prebiotic used in clinical trials 
A list of the probiotic strains and the prebiotic used in the clinical trials is 
presented in Table 4. The doses of probiotic strains ranged from 1.5 × 108 to 
5 × 1010 CFU, and were consumed daily in the probiotic period in the clinical 
trials. The probiotics were administered either as monocultures or mixed 
cultures.  
In the randomised, double-blind, placebo-controlled crossover trial 
(RDBPCCOT) a mixture of probiotics (L. fermentum ME-3, L. paracasei 
8700:2, B. longum 46) in capsules was applied. In addition, the participants 
consumed fructo-oligosaccharide (raftilose P95, Orafti, Belgium) in the above 
mentioned study. In the placebo period of the randomised, double-blind, 
placebo-controlled crossover trial (RDBPCCOT) the participants were 
administered maltodextrin. 
The open-label trial (OLT) for assessment of the safety of putative probiotic 
strains was conducted. A mixture of 5 putative probiotic lactobacilli (L. aci-
dophilus 821-3, L. paracasei 317, L. fermentum 338-1-1, L. gasseri 177, L. 
gasseri E16B7) in gelatine capsules at a daily dose of 5 x 1010 CFU was used in 
the first phase of the colonization study. In the second phase of the colonization 
study, the volunteers consumed L. acidophilus 821-3 as a monoculture (daily 
1 × 1010 CFU). 
The doses of L. plantarum TENSIA varied in the probiotic cheeses (26% fat 
content, semi-hard Edam-type) in both safety trials (DBPCT) (2 x 1010 CFU vs 
1.5 × 108 CFU per 50 g cheese per day, respectively). In the placebo period of 
the double-blind, placebo-controlled trial (DBPCT) of both age groups the par-
ticipants consumed control cheese (average 26% fat content, semi-hard Edam-
type cheese without probiotic bacteria). 
The viability of the encapsulated probiotics and putative probiotic lacto-
bacilli, as well as of L. plantarum TENSIA in cheese was checked by culti-
vation before use in the human trials. 
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4.8.5. Data collection in clinical trials 
Anthropometric indices such as weight and height were measured. Body mass 
index (BMI) was calculated as the weight (kg) divided by height squared (m2) 
(WHO, 1998). Clinical parameters included blood pressure measurements and 
blood sampling.  
The volunteers of the trials were daily or once a week questioned about their 
general welfare, intestinal function (flatulence, bloating, stool frequency, abdo-
minal pain) and adverse effects. 
The blood samples from the antecubital vein, faecal and urine samples were 
collected before and at the end of all clinical trials. 
The following blood indices were measured: inflammatory markers (white 
blood cells (WBC), high sensitive C-reactive protein (hs-CRP)), haematological 
indices (haemoglobin, red blood cells, and platelets) and liver and kidney 
functional indices (aspartate aminotransaminase (ASAT), alanine aminotransa-
minase (ALAT), albumin and serum creatinine), metabolic indices (blood 
glucose, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides). 
The standard laboratory methods were applied using certified assays in the local 
clinical laboratory. 
For measurement of oxidative stress-related parameters like total 
antioxidative activity (TAA), total antioxidative status (TAS), ratio of oxidized 
to reduced glutathione (GSSG/GSH), baseline diene conjugates of low-density 
lipoproteins (BDC-LDL), and the oxidized LDL level (oxLDL) of the blood 
sera were used. Testing of oxidative stress related indices was performed in 
cowork with the researchers of the Department of Biochemistry of University of 
Tartu. 
To estimate the survival of the consumed putative probiotics and their 
persistence after cessation of consumption up to 15–20 days in GI tract the 
faecal samples were used. The prevalence and counts of the consumed strains 
were assessed by different cultural and molecular methods (arbitrarily primed 
polymerase chain reaction (AP-PCR), PCR-denaturing gradient gel electro-
phoresis (PCR-DGGE), real-time PCR) were applied. The real-time PCR was 
performed in Karolinska Institute in Sweden.  
The survival and persistence of L. plantarum TENSIA was evaluated using 
the above mentioned methods, exept PCR-DGGE. 
 
 
4.8.5.1. Measurement of oxidative stress related  
indices in synbiotic trial 
Blood samples were collected from the antecubital vein before and after treat-
ment of probiotics. Serum was analysed for total antioxidative activity (TAA), 
total antioxidative status (TAS) and ratio of oxidized to reduced glutathione 
(GSSG/GSH) (present study).  
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The following oxidative stress related markers, such as blood TAA, TAS, 
GSSG/GSH (paper II), baseline diene conjugates of low-density lipoproteins 
(BDC-LDL) and the oxidized LDL level (oxLDL) were measured (present 
study, Mikelsaar et al., 2008). 
TAA of serum was assessed by the linolenic acid test (LA-test) as described 
previously by Kullisaar et al. (2002). This test evaluates the ability of the blood 
sera to inhibit lipid peroxidation. 
TAS of serum was measured with commercially available kit (TAS, Randox 
Laboratories Ltd. Ardmore, UK) as described elsewhere (Kullisaar et al., 2003), 
water-soluble vitamin E (Trolox) serving as standard. This method is based on 
the inhibition of the absorbance of the ferrylmyoglobin radicals of 2,2’-
azinobis-ethylbenzothiazoline 6-sulfonate (ABTS+) generated by activation of 
metmyoglobin peroxidase with H2O2 and indicates the antioxidativity of the 
blood sera in water fractions. 
Total glutathione and oxidized glutathione were measured by using the 
method of Griffith (1980) as described elsewhere (Kullisaar et al., 2003). The 
glutathione content was calculated on the basis of a standard curve generated 
with known concentration of glutathione. Amount of GSH was calculated as a 
difference between the total glutathione and GSSG (total glutathione – GSSG = 
GSH). The glutathione content was expressed as the ratio of oxidized to reduced 
glutathione (GSSG/GSH).  
The levels of the oxidized low-density lipoprotein (oxLDL) were measured 
using an enzyme-linked immunosorbent assay kit (Mercodia, Uppsala, 
Sweden).  
Baseline diene conjugates of LDL were measured by determining the level 
of LDL diene conjugates using a method that has been validated and reported in 
detail (Ahotupa et al., 1998). In brief, serum LDL was isolated by precipitation 
with buffered heparin citrate. The amount of peroxidized lipids in the samples 
was determined by the degree of conjugated diene double bonds. Lipids were 
extracted from the samples by a mixture of chloroform and methanol (2:1), 
dried under nitrogen, redissolved in cyclohexane, and analysed spectropho-
tometrically at 234 nm. For BDC-LDL, the coefficient of variance for within-
assay and between-assay precision was 4.4% and 4.5%, respectively. 
 
 
4.8.6. Detection of Helicobacter pylori in faeces by a stool kit 
(Papers II) 
The presence of H. pylori was tested in 53 healthy adult volunteers without 
gastric symptoms who participated in the randomised, double-blind, placebo-
controlled crossover trial. 
H. pylori colonization was tested from faecal samples at the beginning of the 
study as a baseline value and at the end of the study applying the HpSA-test 
(ImmunoCard STAT HpSA, Meridian Bioscience Europe, Milan, Italy) 
14 
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(Andreson et al., 2003; Krogfelt et al., 2005). According to the results of the 
HpSA-test the subjects were divided into H. pylori-positive and H. pylori-
negative study group.  
 
 
4.9. Statistical analysis 
Statistical analysis was performed using SigmaStat (Jandel Scientific, San 
Rafael CA, USA) and R 2.6.2 (A Language and Environment, http://www.r-
project.org). The following tests were employed: Fisher exact test, Student’s  
t-test or Mann-Whitney rank sum test (comparison of antagonistic activity of 
probiotic), paired t-test or Wilcoxon signed rank test (comparisons of bio-
chemical indices in human trials), Spearman rank order correlation (com-
parisons between antimicrobial activity and the production of organic acids). 
Data of antioxidative and antagonistic activity of probiotics were analysed using 
a Student’s t-test or Mann-Whitney rank sum test with the Bonferroni correction 
for multiple groups. 
The differences were considered significant when p value was < 0.05. 
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5. RESULTS AND DISCUSSION 
5.1. Functional properties of probiotics and  
putative probiotics 
5.1.1. Screening for colonizing potential  
(auto-aggregation ability, acid, bile and pancreatin tolerance) 
and haemolytic activity of putative probiotics 
We tested auto-aggregation ability, and acid, bile and pancreatin tolerance as 
indicators of a simulated GI environment and haemolytic activity of lactobacilli 
strains. The strains were scored according to the results of auto-aggregation and 
acid, bile, and pancreatin tolerance (Table 5).  
All tested putative probiotic strains showed similar bile and pancreatin 
tolerance to tested concentrations, while differences in acid tolerance and auto-
aggregation were detected.  
The main differences between Lactobacillus strains were found in score of 
auto-aggregation and survival at low pH. The highest score was shown by 
L. acidophilus 821–3 and L. gasseri E16B7. According to the scoring results, 
the sum of L. acidophilus 821–3 showed the highest and L. plantarum TENSIA 
the lowest score (Table 5). Similarly to our study, differences in the acid 
tolerance but also in the bile tolerance of intestinal Lactobacillus strains have 
been demonstrated elsewhere (Delgado et al., 2007). 
The ability to survive in and to adhere to the GI tract is the presumed 
desirable characteristics required for probiotic activity of lactobacilli (Morelli, 
2000). Thus, selected bile- and acid-tolerant and good adherent strains manifest 
good transit tolerance; hence, they may be able to survive in the harsh 
environmental conditions of the human GI tract (FAO/WHO, 2002).  
Detection of the haemolytic potential of putative probiotics is required for 
safety reasons (FAO/WHO, 2002). In our study putative probitic strains were 
tested for haemolytic activity using either human or horse blood. None of the 
tested lactobacilli caused the lysis of erythrocytes on human and horse blood 
agar while complete lysis (-haemolysis) was registered in case of positive 
controls (Streptococcus pyogenes and Staphylococcus aureus). This finding is 
in accordance with a previous study showing non-haemolytic activity among 
dairy and human origin lactobacilli (Maragkoudakis et al., 2009). 
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Table 5. Auto-aggregative properties and acid, bile and pancreatin tolerance of six 
putative probiotic Lactobacillus strains and of the probiotic L. plantarum TENSIA. 
Putative 
probiotic 
strains 
Species 
Auto- 
aggre-
gationa 
Survival at 
pH b 
Oxgall 
(% w/v)c 
Pancreatin 
(% w/v)d Score 
821-3 L. acidophilus 2 2 2 2 8 
E16B7 L. gasseri 2 1 2 2 7 
177 L. gasseri 2 0 2 2 6 
317 L. paracasei 1 1 2 2 6 
338-1-1 L. fermentum 1 1 2 2 6 
1-4-2A L. paracasei  1 1 2 2 6 
TENSIA L. plantarum 0 1 2 2 5 
aAuto-aggregation: score 0, no aggregation; score 1, intermediate aggregation; and score 2, strong 
aggregation; bAcid tolerance: score 0, survival only at pH > 3.0; score 1, survival at pH 3.0; and 
score 2, survival at pH ≤ 2.5; cBile tolerance: score 0, no survival at oxgall concentration 2% 
(w/v); score 2, survival at oxgall concentration 2%; dPancreatin tolerance: score 0, no survival at 
pancreatin concentration 0.5% (w/v); score 2, survival at pancreatin concentration 0.5%. 
 
 
5.1.2. Antibiotic susceptibility pattern of putative probiotics 
In this study, all tested Lactobacillus strains were susceptible to ampicillin, 
gentamicin, erythromycin, tetracycline, chloramphenicol and rifampicin. This 
shows that the tested strains are phenotypically susceptible to antibiotics 
belonging to the EFSA list for mandatory testing. L. fermentum 338-1-1,  
L. paracasei 317 and L. paracasei 1-4-2A were resistant to vancomycin. All 
tested strains were resistant to ciprofloxacin except L. paracasei 1-4-2A and  
L. fermentum 338-1-1. Trimethoprim-resistant strains were L. gasseri E16B7,  
L. gasseri 177, L. paracasei 317 and L. paracasei 1-4-2A (Table 6). 
In general, there are differences in the antibiotic susceptibility pattern of 
lactobacilli at the species and fermentation type levels (Mändar et al., 2001). 
Different species of lactobacilli have high natural resistance to bacitracin, ce-
foxitin, ciprofloxacin, fusidic acid, kanamycin, gentamicin, metronidazole, 
nitrofurantoin, norfloxacin, trimethoprim/sulphamethoxazole, and vancomycin 
(Danielsen and Wind, 2003; Mikelsaar, 2011). However, natural resistance to 
vancomycin, which is not transferable, is characteristic to FHEL and OHEL 
groups of lactobacilli (Mändar et al., 2001; Delgado et al., 2007). This intrinsic 
resistance to vancomycin is based on the presence of D-Ala-D-lactate in their 
peptidoglycan rather than natural D-Ala-D-Ala dipeptide (Klein et al., 2000). 
In our study, all Lactobacillus strains tested did not express resistance to 
erythromycin or tetracycline. This finding suggests the absence of acquired 
resistance among these intestinal isolates.  
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However, some studies reported the evidence of resistance to erythromycin 
and/or tetracycline among human faecal Lactobacillus isolates (Delgado et al., 
2007). These isolates may harbour acquired resistance genes identified encoded 
resistance to tetracycline (tet (M), tet (W), tet (O) and tet (O/W)), erythromycin 
and clindamycin (erm (B)) (Ammor et al., 2007; Ammor et al., 2008). 
Lactobacillus strains carrying acquired resistance to antimicrobial(s) should 
not be used as probiotics and should therefore be discarded from further testing 
for selection of candidate probiotics (EFSA, 2008). 
 
5.1.3. Antagonistic activity of probiotics 
We aimed to find out the antagonistic activity of commercial probiotic lacto-
bacilli against facultatively anaerobic gram-negative target bacteria: uropatho-
genic E. coli, Salmonella enterica ssp. enterica and Shigella sonnei both in 
microaerobic and in anaerobic conditions using different media and taking 
account of the pathogens’ niche in the GI tract. The antagonistic activity of bi-
fidobacteria (strict anaerobes) was tested only in anaerobic conditions. 
Differences in the antagonistic activity of probiotic strains depending on 
growth environments were found. Namely, L. rhamnosus GG and L. plantarum 
299v demonstrated lower inhibition in anaerobic conditions on solid media 
compared to L. paracasei 8700:2 that belongs to the same fermentation group 
(FHEL). The inhibitory activity of only L. paracasei 8700:2 was not dependent 
on either growth conditions (microaerobic vs anaerobic environment) or growth 
medium (solid vs liquid media) (Table 7). The antagonistic activity of 
L. acidophilus La5 (OHOL) was the weakest in microaerobic conditions, while 
the increase in anaerobic conditions was significant. Similarly, the weakest 
antimicrobial activity of the OHOL group, which increases in anaerobic condi-
tions, has been shown in an earlier study (Annuk et al., 2003). 
In contrast to our findings, Annuk et al (2003) reported that the antagonistic 
activity of the OHEL group decreased in an anaerobic milieu. We found that the 
antagonistic activity of L. fermentum ME-3 (OHEL group) increased in anaero-
bic mileu, and L. fermentum ME-3 was the most active probiotic Lactobacillus 
strain in anaerobic conditions on a solid medium (Table 7).  
L. plantarum 299v (FHEL group) demonstrated the highest antagonistic 
activity under microaerobic conditions but its inhibitory effect decreased sig-
nificantly under anaerobic conditions. Similarly, L. plantarum TENSIA showed 
also high antagonistic activity in a microaerobic environment. In contrast to this 
finding, Annuk and co-workers have shown that the OHEL group has higher 
inhibitory activity compared to the FHEL group (Annuk et al., 2003). Thus, our 
study showed that the antagonistic activity of the probiotic is more strain-
specific than fermentation type specific. 
Bifidobacteria (B. lactis Bb12 and B. longum 46) did not suppress 4 facul-
tatively anaerobic gram-negative target bacteria on solid agar but their inhibi-
tory effect was detectable using a liquid medium. There was no significant 
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difference in inhibitory activity (pathogens inhibition values were in the range 
3.2 up to 6.1 log10 CFU/ml) between the Bifidobacterium strains. 
Table 7. Antagonistic activity of the commercial probiotic lactobacilli and of the 
probiotic L. plantarum TENSIA grown in microaerobic and anaerobic environments 
against gram-negative (two uropathogenic E. coli strains, Salmonella enterica ssp. 
enterica and Shigella sonnei) tested on modified MRS agar and liquid media (expressed 
as mean  SD). 
OHEL ME3 22.8  4.60 23.6  2.0 <0.001 5.1  1.9 5.6  1.4 0.626 
FHEL GG 22.9  3.50 19.3  1.5 <0.001 4.4  2.0 5.3  1.8 0.213 
 299v 26.7  3.10 21.8  1.1 <0.001 5.5  1.1 3.0  2.4 0.007 
 TENSIA 25.2  0.10 nd nd nd nd nd 
 8700:2 18.8  2.80 18.4  2.0 0.891 6.3  0.7 5.4  1.7 0.326 
OHOL La5 02.7  2.40 15.5  1.2 <0.001 1.2  1.0 4.0  2.0 0.002 
SD, standard deviation; nd, not determined 
p values, difference between the microaerobic and the anaerobic environment 
ME-3, L. fermentum ME-3; GG, L. rhamnosus GG; 299v, L. plantarum 299v; 8700:2, L. para-
casei 8700:2; La5, L. acidophilus La5; TENSIA, L. plantarum TENSIA  
OHOL, obligately homofermentative lactobacilli; OHEL, obligately heterofermentative lacto-
bacilli; FHEL, facultatively heterofermentative lactobacilli 
 
Selected assays for ranking probiotics against target pathogens 
Further, we applied ranking of probiotics according to their antagonistic ability 
against facultatively anaerobic gram-negative pathogens in liquid media that 
resemble the gastrointestinal environment better than solid media. Different 
probiotics were ranked as expressing high, moderate and low activity in 
different atmospheric conditions mimicking the milieu in the GI tract (Table 8).  
The pyelonephritic strain of E. coli (ATCC 700336) was highly suppressed 
by L. rhamnosus GG and both strains of bifidobacteria, but no significant 
activity was found against cystitic E. coli (ATCC 700414). Effective probiotics 
against S. enterica ssp. enterica were L. paracasei 8700:2, L. plantarum 299v 
and L. fermentum ME-3 showing high activity in a microaerobic milieu. 
L. fermentum ME-3 and both bifidobacteria expressed high activity against 
S. sonnei in an anaerobic milieu. 
Antagonistic activity against H. pylori was evaluated only on solid media. 
The highest antagonistic activity (Figure 3) was expressed by B. longum 46 
(p<0.05) anaerobically. However, under microaerobic conditions characteristic 
of the stomach, high antagonistic activity was expressed by lactobacilli 
belonging to the FHEL group (L. paracasei 8700:2, L. rhamnosus GG and 
L. plantarum 299v).  
Group Strain 
Solid medium (inhibition zone 
values, mm) 
Liquid medium (inhibition, 
log10 CFU) 
Microaerobic Anaerobic p value Microaerobic Anaerobic p value 
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K. Lõivukene showed that the fermentation pattern of lactobacilli did not 
correlate with their antagonistic activity against H. pylori (Lõivukene, 2003). In 
contrast to that study, we found a significant difference in the antagonistic 
activity of lactobacilli according to their fermentation pattern. The FHEL group 
expressed higher antagonistic activity towards H. pylori compared to the other 
fermentation groups. 
The inhibitory activity of probiotic bacteria against the strictly anaerobic 
C. difficile reference strain was low (6–8 mm), expressed by both bifidobacteria 
strains and L. paracasei 8700:2. 
Further research will be needed to confirm if the differences in vitro experi-
ments of the antimicrobial activity of probiotic strains in different environments 
of GI tract biotypes are in accordance with corresponding animal studies. This 
could precede clinical efficacy studies of adjunct treatment with probiotics in 
cure of different gastrointestinal and urinary tract infections. 
 
 
Figure 3. Antagonistic activity of probiotic bacteria against the H. pylori reference 
strain (NCTC 11637) on solid media under microaerobic conditions. Data present 
median inhibition (–) and distribution. Boxes display 25th –75th quartile area, bars 
display 10th–90th percentage area. La5, L. acidophilus La5, LGG, L. rhamnosus GG, 
8700:2, L. paracasei 8700:2; 299v, L. plantarum 299v; ME-3, L. fermentum ME-3; 
B46, B. longum 46; Bb12, B. lactis Bb12. 
B46 > 8700:2 (p=0.001), B46 > ME-3 (p=0.001), 8700:2 > ME-3 (p=0.001) 
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Association between inhibitory activity of lactobacilli and production  
of organic acids and pH  
We did not find significant differences between the production of lactic, acetic 
or succinic acids of the tested probiotic lactobacilli strains either under 
anaerobic or microaerobic conditions (data not shown). However, all tested 
lactobacilli produced to some extent more lactic acids under microaerobic than 
under anaerobic conditions. A higher amount of ethanol was produced by 
L. fermentum ME-3 in the anaerobic environment than in the microaerobic 
environment (96.3 mmol/l vs 54.9 mmol/l). No ethanol was produced by 
L. rhamnosus GG, L. plantarum 299v or L. acidophilus La5.  
Annuk et al. (2003) demonstrated differences in the production of organic 
acids between the fermentation groups of lactobacilli. Namely, the FHEL group 
produced abundant lactic acid and the OHEL group produced acetic acid. 
We found a positive correlation between production of lactic acid and 
inhibitory activity of lactobacilli after cultivation in microaerobic conditions 
(r=0.457; p=0.043, n=20) and inhibitory activity of bifidobacteria after 
cultivation in anaerobic conditions (r=0.862, p=0.005, n=8). The amount of 
acetic acid and the inhibitory activity of lactobacilli and bifidobacteria cultured 
in anaerobic conditions were negatively correlated (r=–0.428, p=0.006;  
r=–0.862, p=0.006, respectively). 
Following microaerobic cultivation, pH values in liquid media correlated 
inversely with antagonistic activity of five probiotic lactobacilli (r=–0.530, 
p=0.016). 
A previous study has revealed correlations between antagonistic activity and 
production of organic acids and pH (Annuk et al., 2003). The findings of our 
study for selection of probiotics or putative probiotics are in concordance with 
the results of the aforementioned study of Annuk and coauthors. 
 
 
5.1.4. Total antioxidative activity of probiotics strains 
In our study the detected indices, i.e. TAA and TAS, include both enzymatic 
and non-enzymatic antioxidative compounds of lactic acid bacteria. The 
probiotic strain L. fermentum ME-3 expressed the highest values of anti-
oxidative activity compared to the other tested probiotic strains (Table 9).  
Annuk et al. (2003) showed that the intestinal lactobacilli belonging to the 
OHOL group expressed the highest TAA values although some particular 
strains from the other groups such as FHEL and OHEL also showed high values 
of TAA. 
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Table 9. Antioxidative activity of probiotic lactic acid bacteria (mean  SD). 
L. acidophilus La5 16  4 0.08  0.06 
L. rhamnosus GG 16  7 0.09  0.03 
L. plantarum 299v 12  5 0.01  0.02 
L. paracasei 8700:2 15  4 0.03  0.03 
L. fermentum ME-3 24  4 0.18  0.05 
B. lactis Bb12 11  6 0.03  0.03 
B. longum 46 11  4 0.10  0.08 
TAA, total antioxidative activity; TAS, total antioxidative status; SD, standard deviation.  
The total antioxidative values of probiotic bacteria were considered high if TAA was >20% and 
TAS was > 0.1 mmol/l. 
All TAA and TAS values of the tested probiotic bacteria versus L. fermentum ME-3 were 
significantly lower (p<0.05) 
 
 
In summary, the functional properties of the tested commercial probiotics are 
variable and strain specific. We found that the uropathogenic strain of E. coli 
was highly suppressed by L. rhamnosus GG and both strains of bifidobacteria. 
L. fermentum ME-3 and both bifidobacteria expressed high activity against 
S. sonnei. The effective probiotics against S. enterica ssp. enterica were 
L. paracasei 8700:2, L. plantarum 299v and L. fermentum ME-3.  
B. longum 46, L. paracasei 8700:2, L. rhamnosus GG and L. plantarum 
299v strains showed moderate antagonistic activity against H. pylori under 
microaerobic conditions on solid media. 
For a further synbiotic trial, three commercial strains (B. longum 46, L. para-
casei 8700:2 and L. fermentum ME-3) were selected according to the results of 
in vitro tests. The probiotic strain L. fermentum ME-3 showed the highest 
antioxidative activity. B. longum 46 expressed the highest antagonistic activity 
against H. pylori. L. paracasei 8700:2 was the only strain whose antimicrobial 
activity did not differ in different growth conditions (microaerobic vs anaerobic 
environment) or in different growth media (solid vs liquid media). 
 
 
5.2. In vivo animal trials 
Two different mice lines, BALB/c and NIH, were used to determine the safety 
of six putative probiotic lactobacilli (L. acidophilus 821-3, L. gasseri E16B7, 
L. gasseri 177, L. paracasei 317, L. paracasei 1-4-2A and L. fermentum  
338-1-1) and of the probiotic L. plantarum TENSIA, respectively. The daily 
doses (109 CFU of probiotic strains) used were concordant with data of 
literature (Pavan et al., 2003). 
Probiotic strains TAA (%) TAS (mmol/l) 
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Oral administration of these lactobacilli did not cause any change in the 
body weight, intestinal inflammation, adverse behavioral effect and general 
health status of the treated mice. The heart blood, liver, kidney and lung 
samples obtained at autopsy were sterile in all mice treated with lactobacilli.  
The spleen culture of one BALB/c mouse (mouse H5, sacrificed on day 5) 
was positive for lactobacilli both on MRS and blood agar media. Two different 
species were identified by API – L. paracasei subsp. paracasei and L. plan-
tarum. AP-PCR typing revealed that the banding pattern of L. plantarum was 
not similar to the fingerprint patterns of any of the Lactobacillus strains that 
were administered to the mice but the banding pattern of L. paracasei subsp. 
paracasei was identical to that of the L. paracasei strain 1-4-2A.  
Mouse H5 with a positive spleen culture showed no pathological changes in 
any of the organs, including the kidney and lungs. The translocated strain 
L. paracasei 1-4-2A was excluded from further study (human trial) as a non-
safe strain for human consumption. 
 
 
5.3. Clinical trials 
5.3.1. Selection of LAB strains for human trials 
Four intervention studies were carried out using monostrain or multispecies 
bacteria in capsules or probiotic cheese comprised L. plantarum TENSIA. 
The bacteria used in these clinical trials were selected according to their 
favourable functional properties and colonizing potential, and earlier confirmed 
safety in animal models (Table 10). The lactobacilli and the bifidobacterium, 
which belonged to the mixture, had no inhibitory effect on each other. 
 
Table 10. Favourable colonizing potential and functional properties of the strains 
serving as the basis for selection of the following clinical trials. 
Strains Favourable functional properties 
L. fermentum ME-3 
L. paracasei 8700:2 
B. longum 46 
high antioxidative activity, antagonistic activity 
antagonistic activity 
antagonistic activity 
L. plantarum TENSIA good viability in simulated GI tract conditions 
confirmed safety in an animal model 
high antagonistic activity 
L. acidophilus 821-3 
L. paracasei 317 
L. fermentum 338-1-1 
L. gasseri 177 
L. gasseri E16B7 
All strains expressed: 
a) good viability in simulated GI tract conditions 
b) confirmed safety in an animal model 
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5.3.2. Performed clinical trials 
Our study included one randomised, double-blind, placebo-controlled crossover 
trial, one open-label trial and two double-blind, placebo-controlled trials. 
The crossover clinical trials were chosen for comparison within an indi-
vidual, as each individual is its own control. As there is usually less variability 
within a subject than between different subjects, the precision of observation 
will increase. A two-week washout period was considered long enough to wash 
out the ingested probiotics because commonly probiotic persists in the GI tract 
less than two weeks (Goldin et al., 1992; Saxelin et al., 1995; Jacobsen et al., 
1999; Mätto et al., 2006). 
The study population of the probiotic cheese studies represented generally 
healthy adults and healthy adults aged over 60 years.  
Health assessment was based on participant interviews conducted prior to the 
study and on self-reported questionnaires for monitoring the symptoms and 
adverse effects, different blood cellular and biochemical indices and several 
measurements, such as measurements of body weight or blood pressure. 
The main purpose of the clinical trials and the drop-outs are shown in Table 
11.  
 
 
5.3.3. Synbiotic trial 
Substantiation of the efficacy of the synbiotic was performed with a controlled 
clinical trial. In our study we tested the efficacy of a probiotic multispecies 
combination (L. fermentum ME-3, L. paracasei 8700:2, B. longum 46) with 
added prebiotic raftilose P95 on oxidative stress related markers of healthy 
adults. 
Healthy volunteers were allocated to receive synbiotic (group 1) or placebo 
(group 2) for 3 weeks. After 2-week washout period the volunteers were crossed 
over to another 3 weeks of placebo or synbiotic administration. Except for the 
fact that more women than men participated in the study (77% vs 23%), the 
subjects were well balanced over the two study groups with respect to baseline 
characteristics such as age, BMI, blood pressure, biochemical indices (glucose, 
lipids) and presence of H. pylori (Table 12). 
There were no significant changes in BMI, blood pressure and blood 
biochemical indices during the synbiotic trial (data not shown). 
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Table 12. Baseline characteristics of the synbiotic study groups (expressed as mean  
 SD). 
 Total group 
(n=53) 
Group 1 
(n=27) 
Group 2 
(n=26) 
Sex (n)    
Female 41 20 21 
Male 12 7 5 
Age (years) 36.3  11.8 34.9  11.7 37.8  12.0 
BMI (kg/m2) 24.7  4.80 25.4  5.60 24.0  3.80 
Blood pressure (mmHg)    
Systolic 122.8  15.50 122.7  15.60 122.8  15.70 
Diastolic 80.3  12.2 80.4  12.4 80.2  12.2 
Glucose, mmol/l 4.8  0.6 4.7  0.5 4.8  0.6 
Total cholesterol, mmol/ 5.2  1.1 5.0  0.9 5.5  1.3 
HDL, mmol/l 1.8  0.3 1.7  0.4 1.9  0.3 
LDL, mmol/l 3.4  1.0 3.2  0.9 3.5  1.2 
Triglycerides, mmol/l 1.2  0.6 1.1  0.5 1.2  0.6 
Presence of H. pylori (yes/no) 28 / 25 13 / 14 15 / 11 
 
 
5.3.3.1. Improvement in oxidative stress related  
markers due to synbiotic intervention 
For detection of oxidative stress related markers, modified, mainly oxidized, 
forms of LDL were tested in blood sera. Oxidized LDL (oxLDL) is an impor-
tant marker of oxidative stress while baseline diene conjugates of LDL  
(BDC–LDL) is a specific indicator of circulating mildly oxidized LDL. 
The BDC-LDL values decreased significantly in the blood of volunteers at 
the end of the synbiotic treatment period compared to baseline values (mean 
15.2 vs 12.7 M/l, p<0.001). A significant reduction was also seen at the end of 
the synbiotic period as compared to the end of the placebo period (mean 12.7 vs 
14.6 M/l, p=0.035) (Figure 4 a). 
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a) 
 
 
b) 
 
Figure 4. Changes in the level of BDC-LDL (a) and in oxLDL (b) values during the 
synbiotic trial. 
BL, baseline; Syn, end of synbiotic consumption; PL, end of placebo period. NS, not significant 
 
 
After the 3-week consumption of the synbiotic product we detected also a 
reduction of oxLDL values, however, similar changes were also found in the 
placebo period (Figure 4 b). The decrease of the oxLDL values in the placebo 
period may be caused by the unexpected carryover effect on synbiotic consump-
tion in the crossover study. There were no significant differences in the oxLDL 
values at the end of the synbiotic period and at the end of the placebo period. 
Clinical studies have shown that BDC-LDL is closely related to athero-
sclerosis and known atherosclerosis risk factors. As an indicator of the risk of 
the disease, BDC-LDL clearly exceeds the sensitivity and specificity of 
common markers, successfully revealing mild oxidation of LDL (Ahotupa and 
Asankari, 1999; Brizzi et al., 2004). The BDC-LDL method distinctly improves 
possibilities for the diagnosis, follow-up of treatment, and basic research of 
cardiovascular diseases. 
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The revealed protection of LDL molecules from oxidative damage is 
evidently due to the high antioxidative properties of L. fermentum ME-3 from 
the probiotic mix. L. fermentum ME-3 is capable of alleviating oxidative stress- 
and inflammation-related damages in the intestinal cells (Truusalu et al., 2004). 
High antioxidative activity has also been detected in probiotic cheese with  
ME-3 (Songisepp et al., 2004). Moreover, the consumption of the probiotic 
L. fermentum ME-3 in fermented goat milk and in capsules increased the total 
antioxidative status (TAS) in healthy subjects (Kullisaar et al., 2003; Songisepp 
et al., 2005).  
 
 
Improvement in blood antioxidative activity in H. pylori-positive subjects 
In our synbiotic study healthy volunteers (n=53) without gastric symptoms were 
divided into two groups according to the presence of H. pylori in the stool 
sample. 28 persons were colonized with H. pylori (53%) and 25 were H. pylori-
negative. H. pylori-positive individuals were significantly older than H. pylori-
negative ones (39.9  11.2 vs 32.3  11.4 years, p=0.018). There was no 
difference in body mass index between the H. pylori-positive and H. pylori-
negative subjects (BMI 25.6  5.0 vs 23.8  4.5, p>0.05). 
We evaluated the impact of consumption of a synbiotic product on the 
antioxidative activity markers of blood (TAS, GSSG/GSH) in asymptomatic H. 
pylori-colonized persons. A positive change in the antioxidative markers was 
the reduction of the ratio of oxidized to reduced glutathione (mean 
0.035  0.027 vs 0.030  0.024, p=0.016) after the consumption of the synbiotic 
compared to baseline values for H. pylori-positive subjects, while no changes 
were found in H. pylori-negative subjects (Figure 5). There were also some 
differences in changes of the ratio of oxidized to reduced glutathione during 
synbiotic and placebo treatment in H. pylori-positive subjects (mean
 0.011 vs –0.001  0.011, p=0.099 (trend)). The decrease in the ratio was 
mainly due to the increase of GSH (972.1 vs 1018.1 g/ml, p=0.063) in 
H. pylori-positive subjects. 
In H. pylori-positive subjects the serum values of TAS were significantly 
lower compared to H. pylori-negative subjects (0.97 vs 1.05 mmol/l, p=0.008). 
After consumption of the synbiotic a beneficial influence was detected: TAS 
values increased in H. pylori-positive persons (0.97 vs 1.03 mmol/l, p=0.004). A 
similar increase in the values of TAS in the placebo period could have been due 
to the carryover effect on synbiotic consumption in the crossover study. No 
changes were found in the TAS values of H. pylori-negative persons. 
Wnuk and co-workers have shown reduced antioxidative activity in the 
saliva of H. pylori-colonized persons (Wnuk et al., 2010). Mashimo et al. 
(2006) have shown that elevated ROS of H. pylori-positive subjects in 
peripheral blood decreased after H. pylori eradication (Mashimo et al., 2006). It 
–0.005 
18 
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has been reported that after successful eradication of H. pylori oxidative stress 
in gastric mucosa was reduced (Pignatelli et al., 2001; Katsurahara et al., 2009). 
Thus, consumption of the synbiotic containing the antioxidative probiotic 
L. fermentum ME-3 may improve reduced systemic antioxidative activity in 
H. pylori-colonized asymptomatic subjects. However, the results need to be 
confirmed in randomised larger studies of H. pylori colonized asymptomatic 
and diseased patients. 
 
 
 
Figure 5. Changes in GSSG⁄GSH values during the trial in H. pylori-positive (n=28) 
and H. pylori-negative (n=25) individuals. 
BL, baseline; Syn, end of synbiotic consumption; PL, end of placebo period. 
 
 
5.4. Safety assessment 
In our studies, according to the self-reported questionnaire, the study subjects 
tolerated the consumption of lactobacilli well although some individual diffe-
rences were noted.  
All haematological and functional indices of the liver and kidney remained 
in a normal range in all participants who completed the trial (Table 13).  
There were no significant differences in BMI and biochemical indices 
(glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides) 
between the consumption of probiotic cheese and control cheese (Table 14). 
The amount of cheese consumed during the study did not cause changes in 
the total cholesterol level of the participants, indicating the safety of the dosage 
of cheese (50 g daily). The dose of consumed cheese was even higher than that 
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used in a study of elderly persons without increased blood cholesterol after daily 
consumption of probiotic cheese (15 g, 109 CFU/day) for 4 weeks (Ibrahim et 
al., 2010). 
Thus, consumption of these Lactobacillus strains (Table 10) can be 
considered safe. This can be stated on the basis of the questionnaire results 
concerning abdominal symptoms without any serious adverse gastrointestinal 
complaints, as well as alterations in the reference ranges of the tested functional 
indices of the kidney and liver, and in inflammatory markers, and total blood 
cholesterol values. 
 
Table 13. Blood inflammatory and functional indices of the kidney and liver assessed in 
human trials (expressed as mean  SD). 
Indices  OLT DBPCT TE1 
DBPCT 
ELD Reference values 
WBC × 109 L 
 
B 
A 
6.0  1.3 
6.1  0.8 
5.2  0.8 
5.6  1.3 
4.9  1.3 
4.8  1.3 
3.5–8.8 × 109/l 
hs-CRP (mg/L) B 
A 
0.7  0.4 
0.8  0.5 
1.1  0.6 
1.0  0.3 
1.6  1.9 
1.8  1.7 
< 5 mg/l 
ASAT (U/L) B 
A 
24.9  7.00 
25.6  6.40
20.2  5.40 
18.3  5.40
21.3  4.50
22.3  4.60
F < 32 U/l 
M < 38 U/l 
ALAT (U/L) B 
A 
21.4  7.50 
25.4  12.9
17.7  5.60 
16.2  4.30
18.5  6.10
21.5  7.20
F < 31 U/l 
M < 41 U/l 
Albumin (g/L) B 
A 
43.1  2.10 
44.3  2.70
45.9  2.60 
45.2  1.80
41.8  2.10
41.8  2.70
34–48 g/l 
Serum creatinine 
(mol/L) 
B 
A 
76.7  15.9 
77.6  10.7
73.8  12.0 
70.9  10.3
64.5  8.90
64.2  10.9
F < 81 mol/l 
M < 107 mol/l 
B, before consumption; A, after consumption 
hs-CRP, high sensitive C-reactive protein; ASAT, alanine aminotransaminase; ALAT, aspartate 
aminotransaminase, F, female, M, male 
DBPCT, double-blind, placebo-controlled trial; placebo-controlled trial; OLT, open-label trial 
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5.5. Survival and persistence of consumed probiotics 
Main preconditions for probiotic impact are the ability to survive and persist in 
the GI environment and to reach high numbers of viable counts in the targeted 
part of the gut after consumption of a probiotic product. Faecal recovery of 
orally administered probiotic strains is a standard method to find out survival 
and persistence in the gastrointestinal tract. It has not been shown earlier how 
the results obtained by in vitro tests of tolerance of lactobacilli could predict the 
behaviour of these particular strains in vivo.  
 
 
Manifestations of the colonizing properties of putative probiotics in human 
organism 
We used cultural and molecular methods to determine the survival and persis-
tence in the GI tract after consumption of the five putative probiotic strains. 
L. acidophilus 821-3 showed the highest score of colonizing potential (auto-
aggregation ability, acid, bile and pancreatin tolerance) in vitro (Table 5). It 
survived and persisted well in the human gut after consumption of mixture of 
five different putative probiotics in capsule form (Table 15).  
Although L. gasseri E16B7 showed good viability in simulated GI tract 
conditions, this strain survived but did not persist in the GI tract of healthy 
volunteers (paper IV). The finding indicates that persistence of lactobacilli in 
the GI tract may be influenced additionally by several other factors such as 
peristalsis, diet, and interactions with the indigenous intestinal microbiota. 
Despite the lowest in vitro data (no auto-aggregation ability) of the colo-
nizing potential of the probiotic L. plantarum TENSIA (Table 5) the strain 
survived well in cheese and therefore was chosen for human studies. In clinical 
studies, L. plantarum TENSIA was detected in faecal samples of five out of 
altogether 30 adults and healthy adults aged over 60 years even after 5 weeks of 
cessation of cheese consumption (Table 16).  
Several earlier studies have demonstrated that dairy products used as 
vehicles for probiotics enhance the tolerance for GI transit (Stanton et al., 
2005). An example is cheese, where the anaerobic environment, high fat content 
and buffering capacity of the matrix helps to protect the probiotic cells both in 
the product and in the intestinal environment.  
The results of our study suggested that the colonizing potential of putative 
probiotics were strain-specific, which is in agreement with some other studies 
(Mishra and Prasad, 2005). The favourable colonizing properties of lactobacilli 
detected in vitro experiments should still be confirmed in human studies with 
and without carrier vechicles. 
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Comparison of different methods for detection of putative probiotics  
In our study we used a conventional plating method with typing AP-PCR and/or 
real-time PCR for detection of consumed Lactobacillus strains in faeces.  
We compared the prevalence and counts of the strain L. acidophilus 821-3 
obtained by real-time PCR assay and by conventional cultivation followed with 
AP-PCR (Table 15). 
There was no difference in the prevalence of L. acidophilus 821-3 using both 
methods but the counts of L. acidophilus 821-3 determined by real-time PCR 
were significantly higher (up to 2 log10 CFU higher) (Table 15). 
These data are in good accordance with previous studies on the topic 
(Ahlroos and Tynkkynen, 2009; Dommels et al., 2009). Real-time PCR 
methods quantify bacterial loads inferred from the number of copies of a par-
ticular DNA target sequence. Thus, this method does not differentiate between 
dead and live bacteria, which lead to an overestimation of the number of viable 
cells. Furthermore, in relation to conventional cultivation methods, not all 
colonies may originate from a single viable cell, which leads to an underesti-
mation of the number of viable cells. In order to obtain a more accurate 
measurement of viable cells using quantitative PCR, Cenciarini-Borde et al. 
(2009) have suggested treating of bacteria with propidinium or ethidium 
monoazide prior to the DNA isolation for selective suppression of amplification 
of DNA released from dead cells (Cenciarini-Borde et al., 2009). 
There was a significant difference between the two methods for evaluation 
of the prevalence of L. plantarum TENSIA in over 60-year-old persons. 
Namely, L. plantarum TENSIA was more often detected in case of real-time 
PCR compared to cultivation with AP-PCR typing (presence/absence of strain – 
0/18 vs 9/9, p=0.001) 2 weeks after cessation of consumption of probiotic 
cheese (Table 16). 
Surprisingly, in case of L. plantarum TENSIA, the counts obtained by real-
time PCR were significantly lower compared to counts obtained by cultivation 
with AP-PCR typing (median 4.2 cell/g vs 6.3 log10 CFU/g p=0.011) in 60-year-
old persons at the end of the consumption of the probiotic (Table 16). This may 
be considered a technical error due to repeated melting of the faecal samples for 
different sets of experiments. 
 
75 
Table 15. Prevalence and counts of recovered L. acidophilus 821-3 (counts in log10 
cfu/g or cell/g in range, median). 
* Mixture of 5 strains: L. acidophilus 821-3, L. paracasei 317, L. fermentum 338-1-1, L. gasseri 
177, L. gasseri E16B7 
 
Prevalence, presence /absence; A, cultivation with typing AP-PCR; B, real time PCR 
 
 
Table 16. Prevalence and counts of recovered L. plantarum TENSIA (counts in log10 
cfu/g or cell/g in range, median). 
Prevalence, presence /absence; A, cultivation with typing AP-PCR; B, real time PCR 
# A significant difference in prevalence of TENSIA using two different methods (p=0.001). 
* A significant difference in counts of TENSIA using two different methods (p=0.011). 
 
 
Different administered doses of putative probiotic 
The L. acidophilus 821-3 was administered in high doses (1 × 1010 CFU) and 
the strain was detected by molecular methods at the end (Day 5) in all persons 
who had consumed this strain (Table 15). 
Saxelin and co-workers have showed that the effective dose for survival and 
persistence is higher than 109 CFU per day. They suggested that the effective 
Study 
Consumption of putative 
probiotics 
Cessation of consumption 
of putative probiotics 
 At beginning 
At end  
(Day 5) Day 8 Day 20 
Phase 1* 
n=9 
A Prevalence 0 / 9 6 / 3 4 / 5 0 / 9 
B  1 / 8 9 / 0 7 / 2 1 / 8 
A Counts, 
log10 cfu/g 
0 0–6.8 (5.8) 0–7.0 (0) 0 
B cell/g 0–5.2 (0) 6.7–8.7 (8.0) 0–8.2 (5.4) 0 – 5.5 (0) 
Phase 2 
n=5 
B Prevalence 0 / 5 5 / 0 5 / 0 1 / 4 
cell/g 0 6.7–8.7 (5.0) 5.3–8.4 (6.0) 0–5.1 (0) 
Studies 
Consumption of putative 
probiotics 
Cessation of consumption 
of putative probiotics 
At beginning At end At beginning At end 
TE1 
n=12 
A Prevalence 0 / 12 10 / 2 2 / 10 1 / 11 
Counts 0 0–8.6 (5.9) 0–4.3 (0) 0–2.6 (0) 
ELD 
n=18 
A Prevalence 0 / 18 15 / 3 0 / 18 # 0 / 18 
B  0 / 18 11 / 7 9 / 9 # 4 / 14 
A Counts, 
log10 cfu/g 
0 0–8.3 (6.3) * 0 0 
B cell/g 0 0–7.6 (4.2) * 0–7.9 (4.2) 0–5.3 (0) 
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daily dose should be 1010–11 CFU (Saxelin et al., 1991; Saxelin et al., 1995). 
Thus, our data are in good concordance with Saxelin’s findings. 
 In a previously conducted randomised, double-blind, placebo-controlled trial 
the consumption of capsules of L. fermentum ME-3 in daily dose 1.5 × 109 CFU 
affected the total count of lactobacilli and the population of L. fermentum. 
However, L. fermentum ME-3 was not detectable at the end of consumption in 
faecal samples using classical cultivation methods (Songisepp et al., 2005). 
 
 
Multi-strain or species combination-based probiotics 
Timmermann et al (2004) has suggested that multispecies probiotics may ex-
press improved functionality as compared to single strain probiotics (Timmer-
man et al., 2004).  
Nevertheless, we found that L. acidophilus 821-3 survived and persisted in 
the GI tract in both cases when administered as a single strain or in a mixture. 
 
 
5.5.1. Changes in counts of faecal lactobacilli 
Our study also demonstrated that administration of Lactobacillus multispecies 
strains changed the counts of faecal lactobacilli (Table 17). Consumption of 
capsules containing a mixture of five putative probiotic strains (L. acidophilus 
821-3, L. paracasei 317, L. fermentum 338-1-1, L. gasseri 177 and E16B7) in 
high doses (5 x 1010 CFU/daily) increased significantly the total intestinal 
lactobacilli count obtained by cultivation (median lactobacilli counts from 5.0 to 
6.6 log10 CFU/g; p=0.014) and by real-time PCR (from 7.2 to 8.2 cell/g; 
p=0.008). 
At the same time, L. acidophilus 821-3 ingested as a monostrain (1 × 1010 
CFU/daily) did not have a similar effect (median lactobacilli count from 7.7 to 
7.6 cell/g, p=0.625) analysed by real-time PCR (Table 17). 
The consumption of probiotic cheese comprising L. plantarum TENSIA for 
3 weeks increased total faecal lactobacilli counts in both study groups (median 
lactobacilli count from 5.9 to 6.7 log10 CFU/g, p=0.047 and from 5.7 to 6.3 
CFU/g, p=0.009, respectively). 
No increase in total lactobacilli counts was seen in the placebo period (Table 
17). 
Mutual interactions take place between a probiotic strain and the host’s 
indigenous microbiota in the small intestine. Some studies showed that 
ingestion of a certain probiotic may increase the total number of indigenous 
lactobacilli (Sepp et al., 1993; Goossens et al., 2003). In a previous trial, the 
consumption of a lower dose (1.5 x 109 CFU/daily) of L. fermentum ME-3 in 
capsules increased significantly the counts of total faecal lactobacilli (by 1.3 
log10 CFU/g, p=0.023) (Songisepp et al., 2005).  
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6. GENERAL DISCUSSION 
For elaboration of a particular probiotic the FAO guidelines are recommended. 
However, up to now it has not been assessed if the in vitro detected functional 
properties and markers of the colonizing potential of particular microbial strains 
are expressed in clinical trials with healthy volunteers. The present thesis was 
aimed to compare the required properties of the probiotic strains obtained by in 
vitro and animal experiments, and their impact on health indices of the human 
organism after consumption. 
First, we aimed to assess the relationship between particular functional 
properties of 7 commercial probiotics and their manifestation in an efficacy 
study using a novel synbiotic, including the selected strains and a prebiotic.  
Second, we aimed to screen the six putative Lactobacillus sp probiotics from 
the Human Microbiota Biobank (Acronym: HUMB registration number: 977) of 
the Department of Microbiology of the University of Tartu. The colonizing 
potential of Lactobacillus spp. and safety in vivo allowed to evaluate the proper-
ties required for the development of a probiotic. Next, the survival, persistence 
and safety of consumption of these putative probiotic strains during healthy 
volunteer trials were assessed. 
The functional properties (e.g. antagonistic and antioxidative activity) of 
commercial probiotics were measured using in vitro tests. We found that the 
probiotic strain L. fermentum ME-3 expressed high antioxidative activity. 
B. longum 46 and L. paracasei 8700:2 showed good antimicrobial activity but 
differences in the suppression of GI pathogens were evident. Three strains 
(B. longum 46, L. paracasei 8700:2 and L. fermentum ME-3) were selected for 
the further synbiotic trial for evaluation of the expression of the functional 
properties in the human organism. In present dissertation we report the efficacy 
of synbiotic consumption reducing the oxidative stress related marker BDC-
LDL of blood sera.  
In our study six putative probiotic lactobacilli strains (L. gasseri 177, 
L. gasseri E16B7, L. acidophilus 821-3, L. paracasei 317, L. fermentum 338-1-1 
and L. paracasei 1-4-2A) originated from faecal samples of healthy Estonian 
and Swedish infants. The colonizing potential (auto-aggregation ability, acid, 
bile and pancreatin tolerance) of the putative probiotics were evaluated in in 
vitro tests. All six strains were considered safe according to the results of in 
vitro tests (no haemolytic activity, no transferable antibiotic resistance). For 
evaluation of the translocation ability of the putative probiotis an animal model 
was used. The translocated strain L. paracasei 1-4-2A was excluded from 
further human trial as a non-safe strain for human consumption. The conducted 
human safety trials showed that consumption of five putative probiotic strains 
and of the probiotic L. plantarum TENSIA in cheese was safe and well tolerated 
according to to the self-reported questionnaire and normal blood indices. All 
five putative probiotics in capsules and L. plantarum in cheese maintained their 
viability and occured in sufficient numbers of live bacteria.  
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In summary, evaluation of probiotics has been based on general and 
functional aspects (Sanders and Huis in’t Veld, 1999) (Figure 6). We have 
modified this scheme according to the results of the present PhD dissertation. 
We differentiated the functional properties for a particular strain and the 
colonizing potential, which are necessary for every probiotic strain. Basing on 
different studies, it was possible to reveal the association between the particular 
in vitro and animal experiments and the clinical results in humans. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Summary of the evaluation of putative and commercial probiotic strains in the 
present dissertation. Green boxes indicate assessed properties of probiotic lactobacilli 
and bifidobacteria in vitro and in vivo. Arrow lines show the detected associations 
between in vitro and human studies. 
Origin of strain 
Biosafety assessment 
 in vitro 
 Animal experiments 
 Clinical trial 
In vitro tests 
1) Colonizing potential: 
 Resistance to gastric and pancreatic 
juice, bile 
 Adherence to intestinal epithelium 
or mucin 
 
2) Particular functional properties: 
 Antagonism to enteric pathogens 
 Production of antioxidative 
compounds 
 Stimulation of immune response
Antimicrobial activity 
Production of organic acids 
Antioxidative activity 
Tolerance in vitro 
Auto-aggregation 
Healthy 1-2-yr-old Estonian 
and Swedish infants – faecal 
sample 
In vitro: 
 No haemolysis 
 No transferable 
antibiotic resistance 
 
No translocation in animals 
 
Well tolerated in volunteers  
Normal blood indices 
(cellular, biochemical) 
Survival and persistence of 
probiotic in gut 
Survival in semi-hard Edam-
type cheese and capsules 
Manifestation of 
antioxidative activity of the 
probiotic in human organism 
in clinical trial 
Clinical trial to evaluate efficacy 
80 
6.1. Functional properties of probiotics 
Evaluation of the antioxidative and antagonistic activity of already commer-
cially available probiotics (five probiotic lactobacilli: L. rhamnosus GG, L. fer-
mentum ME-3, L. acidophilus La5, L. plantarum 299v, L. paracasei 8700:2 and 
of the two probiotic bifidobacteria: B. lactis Bb12, B. longum 46) against 
particular enteric and urinary pathogens (Salmonella enterica ssp. enterica, 
Shigella sonnei, H. pylori, C. difficile and uropathogenic E. coli) in different 
experimental conditions was performed according to the FAO regulations. 
We evaluated the inhibition of pathogens by probiotics in conditions 
resembling the GI niche and found that the uropathogenic E. coli was highly 
suppressed by L. rhamnosus GG and both bifidobacteria strains. Lactobacillus 
strains L. paracasei 8700:2, L. plantarum 299v and L. fermentum ME-3 were 
the most effective against Salmonella enterica ssp. enterica in a microaerobic 
milieu while L. fermentum ME-3 and both bifidobacteria expressed high activity 
against Shigella sonnei in an anaerobic milieu. Inhibitory activity of all tested 
probiotics against C. difficile was low. B. longum 46, L. paracasei 8700:2, 
L. rhamnosus GG and L. plantarum 299v strains showed moderate antagonistic 
activity against H. pylori under microaerobic conditions on solid media 
(Figure 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. High suppression of different pathogens by 6 commercial probiotics. ME-3, 
L. fermentum ME-3; GG, L. rhamnosus GG; 299v, L. plantarum 299v; 8700:2, L. pa-
racasei 8700:2; Bb12, B. lactis Bb12, B46, B. longum 46 
 
 
Stomach 
Small intestine 
Large intestine 
Part of GI tract Pathogens 
H. pylori 
Salmonella enterica 
Shigella sonnei 
Probiotics 
LGG 
ME-3 
8700:2 
Pyelonephritic 
E. coli B46 
Bb12 
299v 
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The functional properties differ significantly among various Lactobacillus 
species and strains (Annuk et al., 2003; Kõll et al., 2008) Therefore, the func-
tional characteristics of a Lactobacillus species or strain cannot be extrapolated 
to the other species or strains without evaluation. 
An important functional characteristic of probiotic is antimicrobial activity 
which is based on production of different antimicrobial compounds. In general, 
the antimicrobial metabolites produced by probiotics can be divided into two 
groups: (i) low molecular mass compounds (bellow 1,000 Da) such as organic 
acids, which have a broad spectrum of action, and (ii) antimicrobial proteins, 
termed bacteriocins (>1.000 Da), which have a relatively narrow specificity of 
action against closely related organisms and other gram-positive bacteria 
(Ouwehand and Vesterlund, 2004).  
Several different in vitro screening techniques (e.g. co-cultured in broth 
media, agar media using for spot-on-lawn assay, well diffusion assay and spot 
and streak line assay) for testing antimicrobial activity of probiotic candidates 
have been applied (Drago et al., 1997; Jacobsen et al., 1999; Annuk et al., 
2003; Moraes et al., 2010). 
It has been shown that the production of organic acids and antimicrobial 
activity of intestinal lactobacilli depend on their growth in different environ-
ments (Annuk et al., 2003). Also biotope and fermentation type of lactobacilli 
may affect antagonistic activity towards pathogens in different environmental 
conditions (Annuk et al., 2003). In addition, it is important to know the niche of 
a particular pathogen in the GI tract. 
Our study showed that the antagonistic activity of a probiotic strain may 
vary in different growth media and in various environmental conditions. At the 
same time, it is important to know the niche of a particular pathogen in the GI 
tract to select probiotic strains with high antagonistic properties in similar 
environmental conditions. The antimicrobial activity of L. fermentum ME-3 has 
been confirmed in animal studies (Truusalu et al., 2004; Truusalu et al., 2008; 
Truusalu et al., 2010). In healthy volunteers, e.g. the targeted group consuming 
functional food, it is complicated to test suppression of different pathogens. 
Thus, the evaluation of antimicrobial activity of probiotics against different 
pathogens in an appropriate in vitro environment should precede clinical 
efficacy studies. 
There was some evidence that lactic acid bacteria (including lactobacilli and 
bifidobacteria) had an anti-oxidative potential (Kaizu et al., 1993; Kullisaar et 
al., 2002; Koller et al., 2008; Kaushik et al., 2009). This antioxidative property 
could favour lactobacilli to colonize the intestines, to protect the intestinal 
mucosa against excessive oxidative stress in the course of inflammation 
(Truusalu et al., 2004; Saulnier et al., 2011). 
We found that the probiotic strain L. fermentum ME-3 expressed high 
antioxidative activity. B. longum 46 and L. paracasei 8700:2 showed good 
antimicrobial activity. Therefore, the three strains (B. longum 46, L. paracasei 
8700:2 and L. fermentum ME-3) were selected for a further synbiotic trial. 
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6.2. Impact of functional properties  
of probiotics on human health 
A number of probiotic species and strains used in clinical trials involving 
human participants, under a variety of conditions, have demonstrated efficacy. 
Recommendations for probiotic use in overtly healthy and diseased population 
according to clinical evidence have been proposed (Floch et al., 2011). 
To be effective, probiotic strains must retain the selected functional charac-
teristic. Food carriers of probiotics may contribute to their survival in the GI 
tract. Lactobacillus fermentum ME-3 in spread cheese has prevented the 
oxidative spoilage of soft cheese products and may act as a natural antioxidant 
in soft cheese spreads with different fats (Jarvenpaa et al., 2007). 
Probiotics have also been used as adjunct to standard therapy for H. pylori 
eradication in clinical trials (Tursi et al., 2004; Tong et al., 2007). H. pylori 
infection causes both local and systemic oxidative stress in patients and, at the 
same time, H. pylori colonization affects negatively the antioxidative defence 
system (Jung et al., 2001; Mashimo et al., 2006). Previous reports indicate a 
decline in the levels of the endogenous cellular antioxidant GSH in gastric 
mucosa; also the decrease of the amount of ascorbic acid in serum and gastric 
juice in H. pylori-positive persons (Banerjee et al., 1994; Verhulst et al., 2000; 
Jung et al., 2001; Shirin et al., 2001). GSH is characterized as the cellular redox 
buffer acting as a scavenger of free radicals and toxic substances, and serving as 
a co-substrate for detoxification enzymes (Hansen et al., 2009). 
Reduction of oxidative stress by probiotics owing to their antioxidant 
properties has been demonstrated using animal models and human trials 
(Naruszewicz et al., 2002; Kullisaar et al., 2003; Truusalu et al., 2004; Wang et 
al., 2009; Truusalu et al., 2010; Kullisaar et al., 2011). Reduction of oxidative 
stress can be assessed by measuring the decrease of oxidative stress markers 
and/or increase of antioxidative defence markers. 
In our previous study, antioxidative defence markers (TAA, TAS) of the 
blood of healthy volunteers increased significantly after 3-week consumption of 
L. fermentum ME-3 as a monostrain (Songisepp et al., 2005).  
Consumption of a dairy product comprising L. fermentum ME-3 has 
demonstrated reduction of oxidative stress in healthy volunteers. Namely, a  
3-week consumption of goat milk fermented with ME-3 significantly improved 
the oxidative status (lowered BDC-LDL level in the plasma lipoprotein fraction, 
diminished level of oxLDL and suppressed production of 8-isoprostanes) and 
enhancement of TAS in the blood of humans (Kullisaar et al., 2003). A very 
recent study showed that 2-week consumption L. fermentum ME-3 kefir 
reduced postprandial oxidative stress (decreased oxLDL, BDC-LDL and 8-
isoprostanes) and decreased postprandial blood triglyceride level in clinically 
healthy subjects (Kullisaar et al., 2011).  
Some evidence suggests that treatment with L. fermentum ME-3 decreases 
oxidative stress in particular diseases e.g. atopic dermatitis and brain stroke. A 
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recent study showed that 3-month consumption of L. fermentum ME-3 fer-
mented goat milk improved skin and blood antioxidative markers (GSSG/GSH 
ratio, total antioxidative capacity (TAC)), and decreased blood oxLDL levels in 
patients with atopic dermatitis (Kaur et al., 2008). In addition, consumption of 
L. fermentum ME-3 capsules by brain stroke patients during rehabilitation 
improved their oxidative stress-related indices (GSSG/GSH, oxLDL) with 
significant positive correlation with clinical outcome according to Functional 
Independence Measure and Scandinavian Stroke Scale scores (Kullisaar et al., 
2008). 
Thus, in our study of healthy persons the consumption of capsules containing 
a combination of different probiotic strains, including the antioxidative 
L. fermentum ME-3 strain with prebiotic raftilose P95, improved some general 
oxidative stress markers of blood. Evidently, the improved bioquality of LDL 
particles (BDC-LDL) and the decrease of the ratio of oxidized to reduced 
glutathione (GSSG/GSH) in H. pylori-positive subjects in the synbiotic trial 
were mainly due to the high antioxidative properties of L. fermentum ME-3. 
 
 
6.3. Screening for the colonizing potential of putative 
probiotic strains in in vitro experiments 
Functional requirements for probiotics should be established by using in vitro 
methods and the results of these studies should be reflected in controlled human 
studies. The colonizing potential of probiotics include tolerance to gastric acid, 
pancreatin and bile tolerance, and auto-aggregation, production of antimicrobial 
compounds to establish the niche in the biotope (Saarela et al., 2000). In vitro 
tests examining maintenance of a strain’s ability to tolerate acidic conditions in 
order to survive and grow in presence of bile and pancreatin can predict survival 
of the probiotic in the human organism (Dunne et al., 2001).  
In our study, all six tested putative probiotic strains and the probiotic 
L. plantarum TENSIA showed similar bile and pancreatin tolerance, while 
differences in acid tolerance and auto-aggregation were revealed. The results of 
our study suggest that the colonizing properties of Lactobacillus strains are 
strain-specific, which is in agreement with the findings of other studies (Mishra 
and Prasad, 2005; Delgado et al., 2007). Similarly to our study, differences in 
the acid tolerance but also in the bile tolerance of intestinal Lactobacillus strains 
have been demonstrated (Delgado et al., 2007). 
 The survival of probiotic strains with lower in vitro colonizing potential can 
be increased with suitable food carriers. Semi-hard cheese of Edam type proved 
to be an excellent carrier for L. plantarum TENSIA. 
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6.4. Safety assessment of putative probiotic strains  
in vitro experiments and in animal models 
Despite many successful clinical studies and the long history of the use of 
lactobacilli, basic research for safety evaluation is important to ensure that 
probiotic strains have no potential risk. The FAO/WHO joint guideline has 
suggested several in vitro tests including correct taxonomic identification of 
probiotic strains, detection of the antibiotic resistance pattern and presence of 
antibiotic resistance genes, assessment of certain metabolic activities (e.g.  
d-lactate production) and testing for haemolytic activity for evaluation of the 
safety of probiotic microbes (FAO/WHO, 2002; Sanders et al., 2010). 
In our study the phenotypic identification of putative probiotic strains has 
been confirmed using molecular methods (arbitrarily primed PCR (AP-PCR) 
and by sequencing the 16S RNA gene. 
Correct identification of probiotic strains to the species and strain levels are 
needed for strain selection and characterization, assessments of strain stability 
throughout the manufacturing process of the probiotic product, for proper 
description of the material used in human intervention studies, efficient tracking 
of the probiotic through the host, and for post-market surveillance including 
matching of strains isolated from any suspected infections (FAO/WHO, 2002; 
Sanders et al., 2010). 
Traditional methods (agar-plate cultivation, colony morphology, fermen-
tation patterns) have been used for identification of probiotic strains. Unfor-
tunately, the use of phenotypic tests is inadequate for species level resolution 
and the identification result should in any case be confirmed by molecular 
methods (Huys et al., 2006; Vankerckhoven et al., 2008).  
All putative probiotic strains in our study were susceptible to ampicillin, 
gentamicin, erythromycin, tetracycline, chloramphenicol and rifampicin. The 
absence of phenotypic antimicrobial resistance of the tested Lactobacillus 
strains suggests the absence of transferable acquired resistance among these 
intestinal isolates. 
Several studies provide the evidence of resistance to erythromycin and/or 
tetracycline among human faecal Lactobacillus isolates (Delgado et al., 2007). 
In the last decade, there has arisen concern that the microorganisms used in food 
can be vehicles for transmission of antibiotic resistance genes (EFSA, 2008). 
Therefore, safety assessment of Lactobacillus strains should include detection 
of their antibiotic resistance profile (Bernardeau et al., 2008). 
Some Lactobacillus strains may show alpha haemolysis around colonies on 
blood agar plates (Olano et al., 2001). Detection of the haemolytic potential of 
putative probiotics is required for safety reasons (FAO/WHO, 2002). According 
to our results, the selected putative probiotic strains did not have haemolytic 
capacities. This finding is accordance with a previous study showing non-
haemolytic activity among lactobacilli of dairy and human origin 
(Maragkoudakis et al., 2009). 
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Bacterial translocation is one of the most serious issues of probiotic safety. It 
is important to evaluate the translocation ability of putative probiotics using an 
animal model. It is well known that translocation of administered probiotics or 
commensal Lactobacillus strains may induce infections including bacteremia, 
sepsis, or endocarditis (Liong, 2008). It is important to evaluate the trans-
location ability of putative probiotics using a suitable animal model. 
In our study we used two different lines of experimental mice with similar 
results. Five out of the 6 tested putative probiotic strains did not cause bacterial 
translocation. Only, L. paracasei strain 1-4-2A caused bacterial translocation to 
the spleen. The translocated strain L. paracasei 1-4-2A was excluded from 
further human trial as a non-safe strain for human consumption. 
The probiotic L. plantarum TENSIA did not cause bacterial translocation in 
the animal model. According to safety testing in vitro and in animal models, 
five putative probiotics of Lactobacillus strains and the probiotic L. plantarum 
TENSIA were suitable for further human trials. 
 
 
6.5. Safety evaluation in human trial 
The safety of probiotics should be confirmed in healthy volunteers in controlled 
clinical trials. Although many research tools based on animal models or in vitro 
techniques are available, data from studies of humans are preferred whenever 
possible.  
In our studies, according to the self-reported questionnaire, the study sub-
jects tolerated the consumption of capsulated putative probiotic lactobacilli and 
probiotic cheese comprising L. plantarum TENSIA well although some indi-
vidual differences were noted. All haematological and functional indices of the 
liver and kidney, and inflammatory markers remained in a normal range in all 
participants who completed the trial. Thus, the consumption of all these putative 
probiotic strains can be considered safe, which corresponds to suggestions for 
their evaluation. 
There is evidence showing that lactobacilli in infections have been isolated 
mainly from individuals with underlying health deficiencies (e.g. predisposing 
heart valve defects, cancer, associated infectious diseases, chronic inflammatory 
diseases, etc.) (Cannon et al., 2005; Robin et al., 2010; Sanders et al., 2010; 
Kochan et al., 2011). Moreover, a recent study in patients with severe acute 
pancreatitis, who received a multispecies probiotic preparation, had higher 
mortality compared to the placebo group (Besselink et al., 2009). In most cases 
intestinal commensals were translocated.  
When a probiotic is planned to be investigated for the first time in a specific 
patient group, it is recommended that preliminary pilot safety trials be 
undertaken, which include routine monitoring for adverse events (Whelan and 
Myers, 2010). 
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6.6. Evaluation of survival and persistence of putative 
probiotic strains in human organism 
To be effective, probiotic strains must retain the functional characteristics and 
the colonizing potential for which they were originally selected. Such 
characteristics include the ability to survive transit through the stomach and 
small intestine and to colonize the human GI tract (Tuomola et al., 2001).  
Faecal recovery of orally administered probiotic strains is a standard method 
for survival and persistence in the GI tract. In general, a probiotic strain 
disappears from the GI tract 3 up to 14 days after cessation of probiotic con-
sumption (Saxelin et al., 1995; Alander et al., 1999; Jacobsen et al., 1999; 
Morelli et al., 2003).  
Survival and persistence may be influenced by the origin of lactobacilli and 
particular properties of the strain, as well as by parameters of the probiotic 
product (including food matrix) and features of the host, and by the methods 
used for enumeration (Walter, 2008; Sanders and Marco, 2010). 
For determination of survival and persistence of probiotics in the GI tract 
cultural and molecular methods (e.g. real time PCR) have been applied 
(Songisepp et al., 2005; Ahlroos and Tynkkynen, 2009; Dommels et al., 2009; 
Saxelin et al., 2010). 
In our study we used both methods for determination of the survival and 
persistence of lactobacilli in the GI tract after consumption of Lactobacillus 
strains. 
All five capsulated putative probiotic strains (L. gasseri 177 and E16B7, L. 
paracasei 317, L. fermentum 338-1-1, L. acidophilus 821-3) survived GI 
passage in humans and one of them, namely L. acidophilus 821-3, persisted 
even up to 10 days after cessation of consumption. According to in vitro tests, 
all tested putative probiotic strains showed similar bile and pancreatin tolerance, 
while differences in acid tolerance and auto-aggregation were detected. This 
indicates that survival and persistence is mostly influenced by acid tolerance 
and auto-aggregation. 
The probiotic L. plantarum TENSIA survived well during GI transit and 
persisted even 5 weeks after cessation of the consumption of probiotic cheese. 
This confirmed good acid and bile tolerance obtained in vitro tests. Regardless 
of the absence auto-aggregation in vitro, L. plantarum TENSIA was able to 
persist for over two weeks.  
 
 
6.7. Impact of consumption of putative probiotics  
on indigenous lactobacilli 
Consumption of probiotics may influence the metabolism and population of the 
indigenous microbiota. Mutual interactions take place between a probiotic strain 
and the host’s indigenous microbiota in the small intestine. Probiotics may 
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cause changes in the amount and composition of the indigenous microbiota 
(Songisepp et al., 2005). 
Very recently McNulty and co-workers have suggested that probiotic 
organisms are capable of altering the metabolic properties of a human microbial 
community. This was the result of altered gene expression in the microbiota 
induced by probiotics (McNulty et al., 2011). 
Some studies showed that ingestion of a certain probiotic may increase the 
total number of indigenous lactobacilli (Sepp et al., 1993; Goossens et al., 
2003; Wind et al., 2010). The increase of Bifidobacterium and Lactobacillus sp 
levels in the gut are correlated with numerous health endpoints. Microbiota 
changes due to probiotic intake include increased numbers of related phylo-
types, decreasing pathogens and their toxins, stabilizing bacterial communities 
when perturbed (e.g. with antibiotics), or promoting a more rapid recovery from 
a perturbation (Sanders, 2011). 
In our study the number of indigenous lactobacilli in faeces increased during 
administration of a mixture of putative probiotic strains or L. plantarum 
TENSIA but decreased again when administration stopped. When a particular L. 
acidophilus strain was administered alone the increase of indigenous lactobacilli 
was not seen. This indicates that the effect to increase counts of indigenous 
lactobacilli may be strain specific. 
Thus, the L. acidophilus strain 821-3 with good colonizing potential serves 
as a promising candidate for biotechnological application. The safety and per-
sistence of the probiotic strain L. plantarum TENSIA (EE patent 05340) has 
been approved in clinical trials in healthy adults and in over 60-year-old 
volunteers. 
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7. LIMITATIONS OF THE STUDY 
This thesis has some limitations.  
First, in our synbiotic trial the 53% prevalence of H. pylori colonized per-
sons was an unexpected finding offering the possibility to test the antimicrobial 
activity of the synbiotic components against the pathogen. Unfortunately, the 
design of the trial with application of enterocoated capsules did not allow 
testing of antimicrobial activity against H. pylori in the gastric cavity. The 
remarkable finding was that the systemic antioxidative defence (TAS) values of 
blood in H. pylori colonized persons were lower than in H. pylori-negative 
subjects. Further, a trend for a positive reduction of GSSG/GSH values by 
L. fermentum ME-3 in H. pylori colonized persons was found, offering a 
possibility for its further testing in H. pylori patients with different eradication 
regimens supplemented with the antioxidative probiotic. 
Second, in the case of detection of L. plantarum TENSIA in faecal samples, 
the counts obtained by real-time PCR were significantly lower at the end of the 
consumption of probiotic cheese compared to the conventional plating method 
with AP-PCR typing performed earlier. Probably, the quality of DNA changed 
due to multiple handling in different laboratories. This finding indicates the 
need for simultaneous use of different detection methods for same set of 
experiments. 
Third, the sample size of volunteers for the safety trial was really small but 
pilot studies with strains still under investigation have always been suggested 
with a limited number of participants.  
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8. PRACTICAL APPLICATIONS 
In summary, the thesis established several necessary steps for development of 
probiotics. 
We showed that the antimicrobial activity of probiotics against gastroin-
testinal pathogens should be tested in different environments and conditions 
mimicking the distinct GI niches before application in humans.  
The other functional properties, including antioxidative activity, should also 
be evaluated offering possibilities for influencing the oxidative stress related 
markers as novel approaches. Oxidative stress has been demonstrated as an 
important factor in the pathogenesis of several diseases.  
Screening for putative probiotics in vitro and animal models is necessary to 
find out new putative probiotic strains. Safety assessment of a putative probiotic 
in a pilot study should precede randomised double-blind placebo controlled 
efficacy studies. 
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9. CONCLUSIONS 
1)  The 7 the commercial probiotic strains expressed in vitro variable antimicro-
bial activity against different pathogens. Namely, L. paracasei 8700:2, L. 
plantarum 299v and L. fermentum ME-3 suppressed Salmonella enterica, 
while L. rhamnosus GG, L. plantarum 299v and L. paracasei 8700:2 
inhibited Helicobacter pylori – the pathogens residing in the small intestine 
and in the stomach, respectively. In the anaerobic environment of the lower 
GI tract B. longum 46, B. lactis Bb12 and L. fermentum ME-3 inhibited 
Shigella sonnei, while both bifidobacteria strains and L. rhamnosus GG 
expressed high activity against the pyelonephritic strain of E. coli, respec-
tively. Evaluation of the antimicrobial activity of probiotics against different 
pathogens in an appropriate environment mimicking GI niches should 
precede clinical efficacy studies. 
2)  L. fermentum ME-3 expressed the highest antioxidative activity among the 
tested 7 commercial strains in in vitro experiments. Consumption of the 
synbiotic containing three commercial strains (antimicrobial L. paracasei 
8700:2 and B. longum 46 and antioxidative L. fermentum ME-3) with 
prebiotic raftilose P95 decreased systemic oxidative stress manifested in the 
reduction of the circulating BDC-LDL values of the blood of volunteers, 
proving the antioxidative efficacy of the synbiotic. 
3)  Screening for the colonizing potential of Lactobacillus sp. (auto-aggregation, 
acid and bile tolerance) by in vitro experiments allowed selecting the most 
promising candidates for clinical trials with putative probiotic strains.  
4)  In vitro testing of L. plantarum TENSIA and of the putative 6 probiotic 
strains for absence of haemolytic activity and transferable antibiotic resis-
tance confirmed their safe potential for human application. Additional 
estimation of possible translocation to different organs in an animal model 
helped to exclude the non-safe Lactobacillus strain (L. paracasei 1-4-2A) 
from the human study.  
5)  The putative probiotic strains tolerated well the passage through the GI tract. 
The persistence of a particular strain varied from 3 days up to 5 weeks after 
cessation of the consumption Lactobacillus strains. We suggest that the 
survival of probiotic strains with lower in vitro colonizing potential can be 
increased with suitable food carriers. The semi-hard cheese of Edam type 
was an excellent carrier for L. plantarum TENSIA.  
6)  The administration of the probiotic cheese comprising L. plantarum 
TENSIA and high doses of the capsulated Lactobacillus multistrains did not 
result in any serious adverse gastrointestinal complaints and/or abnormal 
values of blood indices. Thus, the safety of the capsulated Lactobacillus 
strains and the patented L. plantarum TENSIA strain, elaborated in pro-
biotics was approved in clinical trials with healthy persons, as a basis for its 
application as functional food. 
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11. SUMMARY IN ESTONIAN 
Potentsiaalsete probiootiliste laktobatsillide 
funktsionaalsed omadused, püsivus, ohutus ja tõhusus 
Inimese seedetrakti mikrobioota mõjutab erinevaid bioloogilisi funktsioone. 
Mikrobioota soodustab seedimist, soole epiteelirakkude küpsemist ning mõjutab 
erinevaid füsioloogilisi näitajaid, sh vere lipiidide hulka, inhibeerib kahjulikke 
baktereid ja stimuleerib immuunsüsteemi. 
Vähenenud sündimus ja pikem eluiga on suurendanud krooniliste haiguste 
(nt südame-veresoonkonna haigused, erinevad ainevahetushäired) levimust. 
Lisaks on jätkuvalt olulisel kohal erinevad infektsioonid: respiratoorsed ja uro-
infektsioonid ning toidu teel levivad infektsioonid, samas ka Helicobacter 
pylori infektsioon. Seetõttu vajab elanikkond haiguste ennetamiseks erinevaid 
meetmeid, sealhulgas tervislikumat toitumist. 
Eelpoolnimetatud krooniliste haiguste (sh H. pylori infektsiooni) pato-
geneesis on olulisel kohal oksüdatiivne stress. Mõned piimhappebakterid (sh 
laktobatsillid ja bifidobakterid) omavad antioksüdatiivset aktiivsust, nt suuda-
vad vähendada reaktiivsete hapnikuühendite kuhjumist inimorganismis, produt-
seerivad Mn-superoksiidi dismutaasi, lõhustavad hüdroksüülradikaale ja on 
võimelised alandama oksüdeeritud ja redutseeritud glutatiooni suhet (GSSG/ 
GSH). Senini pole selliste omadustega piimhappebaktereid kasutatud funktsio-
naalse toiduna, et vähendada oksüdatiivset stressi inimorganismis ja sellest 
tulenevalt mõjutada haiguste kulgu. 
Probiootikum on inimeselt pärinev elus mittepatogeenne mikroob, mille 
manustamine on tervisele kasulik. Probiootikumid leevendavad laktoositalu-
matuse sümptomeid, ennetavad toiduallergiat ja parandavad immuunsüsteemi 
võimekust ning taastavad mikrobioota koostist seoses antibiootikumraviga. 
Kuigi probiootikume peetakse üldiselt tervisele ohututeks, on iga potentsiaalset 
probiootikumi vaja põhjalikult testida. Vajalik on tagada probiootikumi tarbi-
mise ohutus, püsimine seedekulglas ning tervistavate omaduste avaldumine 
inimorganismis füsioloogiliste ja biokeemiliste näitajate kaudu. 
2002. aastal soovitasid FAO ja WHO astmelist skeemi probiootikumide 
hindamiseks. See skeem hõlmab vastava mikroobi üldist iseloomustamist in 
vitro, funktsionaalsete omaduste väljaselgitamist ja ohutuse tuvastamist loom-
mudelil. Sellele järgneb tüve ohutuse ja tervistava toime hindamine inimestel 
kliinilistes uuringutes. Samas pole teaduspõhiselt tõestatud probiootikumide 
funktsionaalsete omaduste avaldumist kliinilistes uuringutes tervetel inimestel. 
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Uurimistöö eesmärgid ja ülesanded 
Uurimistöö peamiseks ülesandeks oli hinnata kommertsiaalsete probiooti-
kumide funktsionaalseid omadusi ning potentsiaalsete probiootiliste laktobat-
sillide koloniseerimisvõimet in vitro katsetes. Samas hinnata probiootikumide 
elulemust ja püsivust seedetraktis; probiootikumide ohutust ning efektiivsust 
tervetel täiskasvanutel ja üle 60-aastastel inimestel. 
 
Uurimistöös püstitati järgmised ülesanded: 
1. Hinnata kommertsiaalsete probiootiliste laktobatsillide (L. rhamnosus GG, L. 
fermentum ME-3, L. acidophilus La5, L. plantarum 299v, L. paracasei 
8700:2) ja bifidobakterite (B. lactis Bb12, B. longum 46) entero- ja uropato-
geenide vastast antagonistlikku toimet mikroaeroobses või anaeroobses 
keskkonnas, mis sarnaneb vastavale sooletrakti niššile ning määrata nende 
probiootikumide antioksüdatiivset aktiivsust in vitro katsetes. 
2. Hinnata sünbiootikumi, mis sisaldab antimikroobsete ja antioksüdantsete 
omadustega kolme tüve (L. fermentum ME-3, L. paracasei 8700:2 ja 
B. longum 46) ja prebiootikumi raftiloos P95, tarbimise mõju vere oksü-
datiivse stressi näitajale (oxLDL, BDC-LDL) tervetel inimestel. 
3. Hinnata TÜ mikrobioloogia instituudi Inimese Mikrobioota Biopanga 
(akronüüm: HUMB, Registreerimisnumber: 977) laktobatsillide kollekt-
siooni tüvede koloniseerimisomadusi in vitro eksperimentidega, mis matki-
vad sooles olevaid tingimusi. 
4. Määrata L. plantarum TENSIA ja potentsiaalsete probiootiliste tüvede 
(L. gasseri 177, L. gasseri E16B7, L. acidophilus 821-3, L. paracasei 317, 
L. fermentum 338-1-1, L. paracasei 1-4-2A) ohutust in vitro ja loomkatsetes. 
5. Määrata L. plantarum TENSIA ja potentsiaalsete probiootiliste tüvede 
elulemust ja püsivust seedetraktis tervetel täiskasvanutel ning üle 60-aastatel 
isikutel. 
6. Hinnata L. plantarum TENSIA ja potentsiaalsete probiootiliste tüvede tarbi-
mise ohutust tervetel täiskasvanutel ning üle 60-aastatel isikutel. 
 
Uuritav materjal ja meetodid 
Erinevate kommertsiaalsete probiootiliste tüvede antagonistlikke omadusi uuriti 
erinevates kasvukeskkondades (mikroaeroobne ja anaeroobne) ja kahe erineva 
meetodi (agaril ja puljongis) abil järgnevate mikroobide suhtes: uropatogeenne 
E. coli, Salmonella enterica ssp. enterica, Shigella sonnei, H. pylori ja C. diffi-
cile. Probiootikumide metaboliite (äädik-, piim- ja merivaikhappe ning etanooli) 
määramiseks vedelsöötmes kasutati gaaskromatograafilist meetodit. Lisaks 
uuriti kommertsiaalsete probiootiliste laktobatsillide ja bifidobakterite anti-
oksüdantseid omadusi in vitro eksperimentidega. 
L. plantarum TENSIA ja 6 potentsiaalset probiootilist laktobatsilli tüve 
pärinesid eesti ja rootsi laste roojast. Määrati nende tüvede kolonisatsiooni-
109 
võimet (auto-agregatsiooni, happe- ja sapitaluvust) ning ohutust (hemolüütilise 
aktiivsuse ning ülekantava antibiootikumresistentsuse puudumist). In vitro eks-
perimentidele järgnes ohutuse selgitamine loomkatsetes. L. plantarum TENSIA 
ja 5 sobilike omadustega potentsiaalset probiootilist tüve valiti välja edasiseks 
inimuuringuks, kus määrati nende tüvede tarbimise ohutust ning tüvede elu-
lulemust ja püsivust inimorganismis.  
Probiootikumide funktsionaalsete omaduste avaldumist inimorganismis 
hinnati ühes kliinilises uuringus. Nimelt randomiseeritud topeltpimedas ümber-
lülitusega uuringus hinnati vere oksüdatiivse stressi näitajate muutust isikutel, 
kes tarbisid sünbiootikumi (L. paracasei 8700:2, B. longum 46 ja L. fermentum 
ME-3 koos prebiootikumi raftiloos P95) 3 nädalat. 
 
Uurimistöö kokkuvõte 
Erinevate potentsiaalsete probiootiliste bakterite koloniseerimisvõime määra-
miseks kasutati bakterioloogilisi, biokeemilisi ja molekulaarseid meetodeid. 
Potentsiaalsete probiootikumide ohutuse määramiseks tervetel vabatahtlikel 
kasutati kliinilises praktikas kasutusel olevaid vereanalüüse, antropomeetrilisi 
mõõtmisi ja ankeeti. Randomiseeritud topeltpimedas ümberlülitusega sünbiooti-
kumi uuringus määrati vere oksüdatiivse stressi seotud näitajaid erinevate bio-
keemiliste testidega. 
1.  Viie kommertsiaalse probiootilise laktobatsilli ja kahe probiootilise bifido-
bakteri antimikroobne aktiivsus oli erinevates keskkondades erinev ning 
sõltus konkreetsest probiootikumist ja patogeensest mikroobist. Nimelt 
L. paracasei 8700:2, L. plantarum 299v ja L. fermentum ME-3 inhibeerisid 
S. enterica’t, mis asustab peensoolt ning L. rhamnosus GG, L. plantarum 
299v ja L. paracasei 8700:2 surusid alla H. pylori’t, mis aga asustab magu. 
Anaeroobses keskkonnas, mis on sarnane jämesoolele, inhibeerisid B. lon-
gum 46, B. lactis Bb12 ja L. fermentum ME-3 patogeen Shigella sonnei’d 
ning mõlemad bifidobakterid ja L. rhamnosus GG surusid alla püelonefriiti 
tekitavat E. coli’t. Et hinnata probiootikumide antimikroobset aktiivsust 
erinevate patogeenide suhtes, mis asustavad inimese erinevaid seedetrakti 
piirkondi, tuleb antimikroobset aktiivsust määrata sobilike keskkondade 
tingimustes ning see peaks eelnema kliinilise efektiivsuse uuringutele. 
2.  L. fermentum ME-3 omas kõrget antioksüdatiivset aktiivsust võrreldes teiste 
kommertsiaalsete probiootikumidega in vitro eksperimentides. Kolme 
kommertsiaalse probiootilise tüve funktsionaalsete omaduste avaldumist 
(antimikroobsete L. paracasei 8700:2 ja B. longum 46 ning antioksüdatiivse 
L. fermentum ME-3) koos prebiootikum raftiloos P95-ga hinnati tervete 
täiskasvanute kliinilises uuringus. Sünbiootikumi tarbimine langetas süs-
teemset oksüdatiivset stressi, mis väljendus veres madala tihedusega lipo-
proteiinide dieenkonjugaatide (BDC-LDL) sisalduse vähenemises.  
3.  In vitro eksperimentidega, kus hinnatakse laktobatsillide koloniseerimis-
võimet kirjeldavaid omadusi (autoagregatsioon, happe- ja sapitaluvus), on 
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võimalik kindlaks määrata kõige sobivamaid potentsiaalseid probiootilisi 
laktobatsille inimuuringuteks. 
4.  Tuginedes in vitro ohutuse testidele (hemolüütilise aktiivsuse ja ülekantava 
antibiootikumresistentsuse puudumine) olid kõik potentsiaalsed probiooti-
kumid ja L. plantarum TENSIA ohutud. Vaid üks tüvi (L. paracasei 1-4-2A), 
mis oli ohutu in vitro katsetes, translotseerus hiire põrna. Seda tüve kui 
mitteohutut, inimuuringus ei kasutatud. See leid näitas, et on oluline määrata 
lisaks in vitro testidele ka ohutus loomkatses, vältimaks süsteemseid infekt-
sioone mitteohutute laktobatsillide kasutamisest inimestel. 
5.  Potentsiaalsed probiootikumid säilitasid eluvõime pärast sooletrakti läbimist, 
mis on kooskõlas in vitro testide leiuga. Lactobacillus spp. püsivus soole-
traktis erines tüveti ning kestis kolmest päevast kuni 5 nädalani pärast tüvede 
tarbimise lõpetamist. Madala elulemusega probiootiliste tüvede koloni-
seerimspotentsiaali saab tõsta kui kasutatakse sobivat toidumaatriksit pro-
biootikumi kandjana. Poolkõva Edami tüüpi juust oli L. plantarum 
TENSIA’le sobilik kandja. 
6.  Erinevate kapsuleeritud laktobatsillide tüvede tarbimine kõrgetes doosides ja 
probiootikumina patenteeritud L. plantarum TENSIA tarbimine ei põhjus-
tanud raskeid seedetrakti vaevusi ega ka olulisi muutusi verenäitajates. 
Seega kliiniliste uuringutega tervetel inimestel kinnitus uuritud tüvede 
ohutus, mis on aluseks nende kasutamiseks funktsionaalse toiduna. 
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